Treatment agent, waste liquid treatment tool, and downstream-side waste liquid treatment tool

Abstract

Provided are: a novel treatment agent which is capable of reducing malodors including indole or skatole; further provided is a novel treatment agent which can be applied to at least one of operating rooms, endoscopy rooms, shelters where flush toilets cannot be used, areas without infrastructures such as mountains or shores, and living rooms where nurses are required and where toilets cannot be used by themselves, and the like. The invention discloses a treating agent for treating waste liquid. The treating agent contains slaked lime and pepper.

Description

Technical Field

[0001] The present invention relates to a treatment agent, a waste liquid treatment tool, and a downstream waste liquid treatment tool. Background Art

[0002] Proper treatment of excrement is important for maintaining a hygienic and comfortable environment, but it may become difficult in various situations and places. For example, in evacuation shelters where flush toilets cannot be used during emergencies, in areas without infrastructure such as mountains or coasts, in the rooms of care recipients who cannot go to the toilet by themselves, in operating rooms, endoscopy rooms, etc. within a hospital.

[0003] For example, taking the endoscopy room as an example, endoscopes are divided into upper examinations that examine the stomach, etc. through the mouth or nose, and lower examinations that examine the rectum, large intestine, and small intestine through the anus. Both upper and lower examinations involve aspiration of body fluids, and the examination is carried out while washing with water as appropriate, so that waste liquid mixed with excrement, blood, and body fluids is discharged. The waste liquid containing body fluids thus generated is provided for waste treatment.

[0004] Patent Document 1 discloses a method in which a treatment agent is disposed in a collection container. The treatment agent is for absorbing the waste liquid flowing down into the collection container via a waste liquid introduction pipe and is composed entirely or mainly of a high molecular weight water-absorbing polymer. Thus, the waste liquid sucked and collected into the closed collection container is successively gelled by supplying the treatment agent pre-disposed in the collection container. Therefore, the sucked and collected waste liquid does not scatter outside the collection container, and the safety is excellent.

[0005] Prior Art Documents Patent Documents Patent Document 1: Japanese Patent Laid-Open No. 02-157083 Summary of the Invention Patent Document 1 only mentions problems related to waste liquid treatment, but there is also the problem of malodor from excrement. In particular, malodors such as indole or skatole are very uncomfortable and cause headaches for medical practitioners.

[0006] Therefore, the technical problem of the present invention is to provide a novel treatment agent capable of reducing malodors including indole and skatole, and further to provide a novel treatment agent applicable to at least one of waste liquid treatment in operating rooms, endoscopy rooms, evacuation shelters where flush toilets cannot be used, areas without infrastructure such as mountains or coasts, and the rooms of care recipients who cannot go to the toilet by themselves.

[0007] One aspect of the present invention is a treatment agent containing slaked lime and pepper.

[0008] The treatment agent according to one aspect of the present invention can provide a novel treatment agent capable of reducing malodors including indole or skatole, and further provide a novel treatment agent applicable to at least one of the treatment of liquid waste in operating rooms, endoscopic examination rooms, evacuation shelters where flush toilets cannot be used, areas without infrastructure such as mountains or coasts, and rooms for nursing care recipients who cannot go to the toilet by themselves. In addition, the treatment agent can also be used for the treatment of excreta, blood, vomit or body fluids discharged from humans or animals, or the treatment of organic sludge such as domestic waste. BRIEF DESCRIPTION OF THE DRAWINGS

[0009] Figure 1 It is a color photograph showing the proliferation inhibitory effect of Specimen A on spore-forming bacteria.

[0010] Figure 2 It is a schematic perspective view showing the liquid waste treatment tool of the embodiment and the downstream liquid waste treatment tool.

[0011] Figure 3 is Figure 2 front view of.

[0012] Figure 4 It shows Figure 2 exploded perspective view of the structure of the liquid waste treatment tool of.

[0013] Figure 5 It shows Figure 3 cross-sectional view along the height direction of the inside of the liquid waste treatment tool of.

[0014] Figure 6 It shows the Figure 3 exploded perspective view of the lid part and the partition member constituting the liquid waste treatment tool of.

[0015] Figure 7 It shows at Figure 6 exploded perspective view of the lid part and the partition member cut at a different position from.

[0016] Figure 8 It shows the exploded perspective view of the structure of the partition member.

[0017] Figure 9 It shows the top view of the partition member.

[0018] Figure 10 It shows the Figure 2 exploded perspective view of the structure of the downstream liquid waste treatment tool shown in.

[0019] Figure 11 It shows the cross-sectional view along the height direction of the inside of the downstream liquid waste treatment tool.

[0020] Figure 12It is a perspective view showing a lid portion, a connecting member, and a mounting member that constitute a downstream waste liquid treatment tool, shown in a state where the lid portion is cut off.

[0021] Figure 13 It shows the lid portion, the connecting member, the mounting member, and the displacement member, and shows when gas for suction etc. flows inside the mounting member Figure 11 magnified view.

[0022] Figure 14 It shows in Figure 13 the position of the displacement member is different from Figure 13 magnified view of the state.

[0023] Figure 15 It shows Figure 4 exploded perspective view of a waste liquid treatment tool of a modified example.

[0024] Figure 16 It shows Figure 10 exploded perspective view of a downstream waste liquid treatment tool of a modified example.

[0025] Figure 17 It is a perspective view showing a modified example of a partition member.

[0026] Figure 18 It is Figure 17 exploded perspective view.

[0027] Figure 19 It is Figure 17 top view.

[0028] Figure 20 It is a perspective view showing a modified example of a partition member.

[0029] Figure 21 It shows Figure 13 modified example diagram.

[0030] Figure 22 It shows Figure 14 modified example diagram.

[0031] Figure 23 It shows Figure 1 modified example perspective view.

[0032] Figure 24 It is an exploded perspective view of an interception assembly on which a modified example of a waste liquid treatment tool is installed.

[0033] Figure 25 It is a diagram showing the inside of the interception assembly. Detailed Description

[0034] <First Invention> First, the first invention will be described.

[0035] In this specification, "X to Y" representing a range means "X or more and Y or less". When multiple "X to Y" are recited, for example, when "X1 to Y1 or X2 to Y2" is recited, each value is disclosed as the upper limit, each value is disclosed as the lower limit, and all combinations of their upper and lower limits are disclosed (that is, the legal basis for modification). Specifically, modification to X1 or more, modification to Y2 or less, modification to X1 or less, modification to Y2 or more, modification to X1 to X2, modification to X1 to Y2, etc. must all be regarded as legal. In addition, unless otherwise specified, operations and measurements such as transitivity are measured under the conditions of room temperature (20 to 25 °C) / relative humidity 40 to 50%RH. % means mass % unless otherwise specified.

[0036] <Treatment agent> One aspect of the present invention is a treatment agent for treating waste liquid, containing slaked lime and pepper. According to this aspect, it is possible to reduce the malodor including indole and skatole, and thus it can be applied to the waste liquid treatment of at least one of operating rooms, endoscopic examination rooms, evacuation shelters where flush toilets cannot be used, areas with underdeveloped infrastructure such as mountains or coasts, and rooms for nursing care recipients who cannot go to the toilet by themselves, etc. accompanied by this problem.

[0037] In one embodiment of the present invention, the waste liquid is excrement, blood, vomit or body fluid discharged from a human or an animal. In one embodiment of the present invention, the waste liquid is a liquid (excrement, blood, body fluid, etc.) discharged from a patient during a medical act such as endoscopic examination (upper examination, lower examination). In one embodiment of the present invention, the waste liquid can be human excrement (feces and / or urine) (in the case of only feces, it may include liquids such as water).

[0038] In one embodiment of the present invention, the waste liquid includes at least one selected from the group consisting of n-butyric acid, n-valeric acid, isovaleric acid, indole and skatole as malodor components. In one embodiment of the present invention, the waste liquid contains at least one of indole and skatole as malodor components. The treatment agent in the present invention is effective not only in deodorizing (including reducing odor) of fatty acids such as n-butyric acid, n-valeric acid and isovaleric acid, but also particularly effective in deodorizing (including reducing odor) at least one of indole and skatole. In one embodiment of the present invention, the treatment agent is a treatment agent for deodorizing at least one of indole and skatole.

[0039] (Slaked lime) The treating agent of one embodiment of the present invention contains slaked lime. In one embodiment of the present invention, the content ratio (mass%) of slaked lime in the treating agent is 0.1 mass% or more, 0.5 mass% or more, 1 mass% or more, 2 mass% or more, 3 mass% or more, 5 mass% or more, 6 mass% or more, 7 mass% or more, 8 mass% or more, 9 mass% or more, 10 mass% or more, 12 mass% or more, 15 mass% or more, 17 mass% or more, 20 mass% or more, or 30 mass% or more. In one embodiment of the present invention, the content ratio (mass%) of slaked lime in the treating agent is 70 mass% or less, 60 mass% or less, 50 mass% or less, 40 mass% or less, 35 mass% or less, 30 mass% or less, 28 mass% or less, 25 mass% or less, 20 mass% or less, 15 mass% or less, 14 mass% or less, 13 mass% or less, 10 mass% or less, 9 mass% or less, 8 mass% or less, 7 mass% or less, 6 mass% or less, 5 mass% or less, 4 mass% or less, or 3 mass% or less. In one embodiment of the present invention, the content ratio (mass%) of slaked lime in the treating agent is 0.1 to 40 mass%, 0.5 to 35 mass%, 1 to 30 mass%, 3 to 28 mass%, 5 to 25 mass%, or 7 to 15 mass%.

[0040] In one embodiment of the present invention, the average particle size of slaked lime is, for example, 10 μm or more or 50 μm or more. In one embodiment of the present invention, the average particle size of slaked lime is, for example, 1000 μm or less, 500 μm or less, or 300 μm or less. In addition, the "average particle size" described in this specification, unless otherwise specified, refers to the average value obtained by arbitrarily selecting a statistically reliable number (or 100, 200, 300, or 1000) of particles, measuring the longest particle size for each particle through a microscope, and adding them up and averaging. In addition, in order to achieve the desired average particle size, appropriate sieving or the like can be performed. In one embodiment of the present invention, as a method for preparing slaked lime, a method of purchasing commercially available products is preferred. For example, products of Ube Materials Co., Ltd. are preferred.

[0041] (Pepper) The treating agent of one embodiment of the present invention contains pepper. Pepper is the fruit of the pepper tree of Piper nigrum. In one embodiment of the present invention, the pepper can be any one of black pepper, white pepper, green pepper, and pink pepper.

[0042] In one embodiment of the present invention, the pepper is not in the form of a piperine extract.

[0043] In one embodiment of the present invention, the average particle size of pepper is, for example, 10 μm or more, or 50 μm or more. In one embodiment of the present invention, the average particle size of pepper is, for example, 1000 μm or less, 500 μm or less, or 300 μm or less.

[0044] In one embodiment of the present invention, the content ratio (mass %) of pepper in the treatment agent is 0.05 mass % or more, 0.1 mass % or more, 0.5 mass % or more, 1 mass % or more, 1.5 mass % or more, 1.6 mass % or more, 1.7 mass % or more, 1.8 mass % or more, 2 mass % or more, 2.5 mass % or more, 3 mass % or more, 3.2 mass % or more, 3.5 mass % or more, 3.8 mass % or more, 4 mass % or more, 5 mass % or more, 6 mass % or more, 7 mass % or more, 8 mass % or more, 9 mass % or more, 10 mass % or more, 12 mass % or more, 14 mass % or more, 16 mass % or more, 18 mass % or more, or 20 mass % or more. According to one embodiment of the present invention, the content ratio (mass %) of pepper in the treatment agent is 55 mass % or less, 45 mass % or less, 40 mass % or less, 30 mass % or less, 25 mass % or less, 20 mass % or less, 15 mass % or less, 10 mass % or less, 9 mass % or less, 8 mass % or less, 7 mass % or less, 6 mass % or less, 5.5 mass % or less, 5 mass % or less, 4 mass % or less, 3.8 mass % or less, 3.5 mass % or less, or 3 mass % or less.

[0045] According to one embodiment of the present invention, the content ratio (mass %) of pepper in the treatment agent is 0.05 - 30 mass %, 0.1 - 25 mass %, 0.5 - 20 mass %, 1 - 15 mass %, 1.5 - 10 mass %, 1.6 - 9 mass %, 1.7 - 8 mass %, 1.8 - 7 mass %, 1.8 - 6 mass %, 1.8 - 5 mass %, 1.8 - 4.5 mass %, or 1.8 - 3.8 mass %.

[0046] According to one embodiment of the present invention, these content ratios (mass %) can be values calculated based on the treatment agent containing the binder or values calculated by removing the binder from the treatment agent. In addition, the content ratios (mass %) of the components in the treatment agent described in this specification can be the same as above, values calculated based on the treatment agent containing the binder or values calculated by removing the binder from the treatment agent.

[0047] According to one embodiment of the present invention, the treatment agent may or may not contain a binder. The preferred ranges of the content ratios (mass %) of the respective components in the treatment agent may vary depending on the presence or absence of the binder.

[0048] (Water-absorbing polymer) The treatment agent according to an embodiment of the present invention contains a water-absorbing polymer. By containing the water-absorbing polymer, moisture and the like in the object to be treated are absorbed, and the treated substance is easily solidified (easily becomes colloidal). In this specification, the "water-absorbing polymer (water-absorbing resin)" refers to a polymer gelling agent having a water-swellability (CRC) of 5 g / g or more as defined by ERT441.2-02 and a water-soluble component (Ext) of 50% by mass or less as defined by ERT470.2-02.

[0049] In an embodiment of the present invention, as specific examples of the water-absorbing polymer, for example, starch-based water-absorbing polymers such as starch acrylonitrile graft polymer hydrolyzate and starch acrylic acid graft polymer, cellulose-based water-absorbing polymers such as cellulose-acrylonitrile graft polymer and cellulose-styrene sulfonic acid graft copolymer, polysaccharide-based water-absorbing polymers such as pectin, protein-based water-absorbing polymers such as collagen, polyvinyl alcohol-based water-absorbing polymers such as cross-linked polyvinyl alcohol polymer, acrylic acid-based water-absorbing polymers such as cross-linked sodium polyacrylate, partially sodium salt cross-linked acrylic acid polymer, acrylate-vinyl alcohol copolymer, maleic anhydride-based water-absorbing polymers, vinyl pyrrolidone-based water-absorbing polymers, polyether-based water-absorbing polymers such as polyethylene glycol and cross-linked diacrylate polymer, etc. These water-absorbing polymers can be used alone or in combination of two or more. In addition, these water-absorbing polymers can be synthesized or commercially available products can be used. As examples of commercially available products, for example, AQUAKEEP (registered trademark) SA (manufactured by Sumitomo Seika Chemicals Co., Ltd.), AQUALIC (registered trademark) CA (manufactured by Nippon Shokubai Co., Ltd.), SANFRESH (ST-250, ST-100, ST-573), AQUAPEARL (manufactured by sundiapolymer Co., Ltd.), hymosub HS-960 (manufactured by hymo Co., Ltd.), EF Polymer (manufactured by EF Polymer Private Limited), etc.

[0050] In an embodiment of the present invention, the water-absorbing polymer can be carboxymethyl cellulose. Carboxymethyl cellulose is a derivative of cellulose, in which carboxymethyl (-CH2-COOH) is bonded to a part of the hydroxyl groups of the pyranose monomers constituting the cellulose backbone. In addition, the carboxymethyl cellulose can be a carboxymethyl cellulose salt. Carboxymethyl cellulose has a high affinity for water and is a thickener that forms a gel-like high-viscosity body by mixing with water. In the present invention, the treatment agent is thickened, so that the odor suppression effect is improved and the suppression effect can be further maintained.

[0051] According to one embodiment of the present invention, the average particle diameter of the water-absorbing polymer is 1 to 1200 μm, 50 to 1100 μm, 10 to 1000 μm, 80 to 850 μm, 100 to 600 μm, 150 to 500 μm, or 200 to 400 μm.

[0052] According to one embodiment of the present invention, the content ratio (% by mass) of the water-absorbing polymer in the treatment agent is 1% by mass or more, 5% by mass or more, 10% by mass or more, 15% by mass or more, 20% by mass or more, 25% by mass or more, 28% by mass or more, 30% by mass or more, 35% by mass or more, 40% by mass or more, 45% by mass or more, 50% by mass or more, 55% by mass or more, 60% by mass or more, or 65% by mass or more. According to one embodiment of the present invention, the content ratio (% by mass) of the water-absorbing polymer in the treatment agent is 99% by mass or less, 95% by mass or less, 90% by mass or less, 85% by mass or less, 80% by mass or less, 75% by mass or less, 70% by mass or less, 65% by mass or less, 60% by mass or less, 55% by mass or less, 50% by mass or less, 45% by mass or less, 40% by mass or less, or 35% by mass or less.

[0053] According to one embodiment of the present invention, the content ratio (% by mass) of the water-absorbing polymer in the treatment agent is 1% to 99% by mass, 5 to 95% by mass, 10 to 90% by mass, 15 to 85% by mass, 20 to 80% by mass, 25 to 75% by mass, 30 to 70% by mass, 35 to 65% by mass, 40 to 60% by mass, or 45 to 55% by mass. According to one embodiment of the present invention, the content ratio (% by mass) of the water-absorbing polymer is 25 to 60% by mass.

[0054] (zinc oxide) According to one embodiment of the present invention, the treatment agent contains zinc oxide. Zinc oxide is an oxide of zinc represented by ZnO and has the effect of adsorbing odor components such as ammonia and sulfides and deodorizing. As zinc oxide, it can be freely selected from commercially available products. For example, zinc oxide type I (manufactured by hakusuitech Co., Ltd.), zinc oxide type II (manufactured by hakusuitech Co., Ltd.), Pazet AB, Pazet AK, Pazet CK (all manufactured by hakusuitech Co., Ltd.) etc. can be cited.

[0055] According to an embodiment of the present invention, the content ratio (mass %) of zinc oxide in the treatment agent is 0.05 mass % or more, 0.1 mass % or more, 0.25 mass % or more, 0.5 mass % or more, 1 mass % or more, 1.5 mass % or more, 2 mass % or more, 2.5 mass % or more, 3 mass % or more, 3.5 mass % or more, 3.8 mass % or more, 4 mass % or more, 4.2 mass % or more, 4.4 mass % or more, 4.6 mass % or more, 4.8 mass % or more, 5 mass % or more, 5.2 mass % or more, 5.4 mass % or more, 5.6 mass % or more, 5.8 mass % or more, 6 mass % or more, 6.2 mass % or more, or 6.4 mass % or more.

[0056] According to an embodiment of the present invention, the content ratio (mass %) of zinc oxide in the treatment agent is 30 mass % or less, 25 mass % or less, 23 mass % or less, 20 mass % or less, 18 mass % or less, 15 mass % or less, 10 mass % or less, 9 mass % or less, 8 mass % or less, 7 mass % or less, 6 mass % or less, 5 mass % or less, 4 mass % or less, or 3 mass % or less.

[0057] According to an embodiment of the present invention, the content ratio (mass %) of zinc oxide in the treatment agent is 0.05 - 30 mass %, 0.1 - 25 mass %, 0.5 - 20 mass %, 1 - 15 mass %, 2 - 10 mass %, 2.5 - 8 mass %, 3 - 6 mass %, 3.5 - 5 mass %, or 3.8 - 4 mass %. According to an embodiment of the present invention, the content ratio (mass %) of zinc oxide is 2.5 - 30 mass %.

[0058] (Lignin) According to an embodiment of the present invention, the treatment agent contains lignin. Lignin is a high - molecular phenolic compound involved in the lignification of higher plants and is also called lignin. Lignin can exert the effect of adsorbing and decomposing ammonia and other odor substances.

[0059] According to an embodiment of the present invention, the content ratio (mass %) of lignin in the treatment agent is 0.01 mass % or more, 0.05 mass % or more, 0.1 mass % or more, 0.5 mass % or more, 0.8 mass % or more, 1 mass % or more, 1.2 mass % or more, 1.5 mass % or more, or 1.8 mass % or more. According to an embodiment of the present invention, the content ratio (mass %) of lignin in the treatment agent is 30 mass % or less, 25 mass % or less, 20 mass % or less, 15 mass % or less, 10 mass % or less, 8 mass % or less, 6 mass % or less, 4 mass % or less, 3.5 mass % or less, 3.3 mass % or less, 3.1 mass % or less, 3.0 mass % or less, 2.8 mass % or less, 2.6 mass % or less, or 2.4 mass % or less.

[0060] According to an embodiment of the present invention, the content ratio (mass %) of lignin in the treatment agent is 0.01 to 30 mass%, 0.05 to 25 mass%, 1 to 20 mass%, 1.5 to 15 mass%, 1.5 to 10 mass%, 1.5 to 8 mass%, 1.5 to 6 mass%, 1.5 to 4 mass% or 1.5 to 3 mass%. According to an embodiment of the present invention, the content ratio (mass %) of lignin is 1 to 3.5 mass%.

[0061] According to an embodiment of the present invention, the average particle diameter of lignin is 1 to 500 μm, 5 to 300 μm, 10 to 100 μm or 40 to 80 μm.

[0062] In an embodiment of the present invention, as a method for preparing lignin, a method of purchasing commercially available products is preferred, and examples thereof include SanX, VANILLEX (manufactured by Nippon Paper Industries Co., Ltd., etc.).

[0063] (Bentonite) According to an embodiment of the present invention, the treatment agent contains bentonite. Bentonite contains a large amount of layered aluminum silicate and has properties such as high viscosity, adhesiveness, water absorbency or adsorbability. Bentonite adsorbs cations such as ammonia and inhibits and adsorbs the generation of ammonia and other odor substances. In addition, by combining lignin and bentonite, the adsorption effect of the cations of bentonite and the unknown complex three-dimensional network structure of lignin act synergistically, and the effect of inhibiting, adsorbing and decomposing the generation of ammonia and other odor substances can be further exerted.

[0064] According to an embodiment of the present invention, the content ratio (mass %) of bentonite in the treatment agent is 0.01 mass% or more, 0.05 mass% or more, 0.1 mass% or more, 0.5 mass% or more, 0.8 mass% or more, 1 mass% or more, 1.2 mass% or more, 1.5 mass% or more or 1.8 mass% or more. According to an embodiment of the present invention, the content ratio (mass %) of bentonite in the treatment agent is 30 mass% or less, 25 mass% or less, 20 mass% or less, 15 mass% or less, 10 mass% or less, 8 mass% or less, 6 mass% or less, 4 mass% or less, 3.5 mass% or less, 3.3 mass% or less, 3.1 mass% or less, 2.8 mass% or less, 2.6 mass% or less or 2.4 mass% or less.

[0065] According to an embodiment of the present invention, the content ratio (mass%) of bentonite in the treatment agent is 0.01 mass% to 30 mass%, 0.05 to 25 mass%, 0.1 to 20 mass%, 1 to 15 mass%, 1.5 to 10 mass%, 1.5 to 8 mass%, 1.5 to 6 mass%, 1.5 to 4 mass%, or 1.5 to 3.5 mass%. According to an embodiment of the present invention, the content ratio (mass%) of bentonite in the treatment agent is 1 to 3.5 mass%.

[0066] According to an embodiment of the present invention, the average particle size of bentonite is 0.05 to 300 μm, 0.5 to 200 μm, 10 to 150 μm, 50 to 148 μm, or 80 to 145 μm. According to an embodiment of the present invention, the volume average particle size (D50) of bentonite is 0.05 to 300 μm, 0.5 to 200 μm, 10 to 150 μm, 50 to 148 μm, or 80 to 145 μm. According to an embodiment of the present invention, the mode diameter of bentonite is 0.05 to 300 μm, 0.5 to 200 μm, 10 to 150 μm, 50 to 148 μm, or 80 to 145 μm.

[0067] In an embodiment of the present invention, as a method for preparing bentonite, a method of purchasing commercially available products is preferred. For example, KUNIPIA-F, KunimineF, MOISTNITES, MOISTNITEU (manufactured by Kunimine Industries), or 250SA-B (manufactured by Toyo Bentonite Mining Co., Ltd., etc.) can be cited.

[0068] (Zeolite) According to an embodiment of the present invention, the treatment agent contains zeolite. "Zeolite" is a general term for minerals called zeolite group, and about 40 kinds of natural zeolites have been discovered. By containing zeolite, the pores of the zeolite can absorb malodors and suppress malodors. The zeolite can be natural or artificial, and is preferably artificial from the viewpoint of availability. In addition, the zeolite of the present invention is preferably a zeolite called mordenite having extremely small cavities of about 5.5 to 8 Å, which is slightly larger than water or nitrogen molecules, and having a tunnel-like structure. In the case of purchasing a commercially available product of zeolite, zeolite 2460, zeolite 60, zeolite CP, ZEOFILL (registered trademark) series, etc. manufactured by Shin-Tohoku Chemical Industry Co., Ltd. are preferably used. The average particle size of the zeolite is not particularly limited, and is about 5 μm to 1.5 mm, or about 8 μm to 1.2 mm, or about 10 to 100 μm. In the zeolite, SiO2 (silicon oxide), Al2O3 (aluminum oxide), CaO (calcium oxide), Na2O (sodium oxide), K2O (potassium oxide), Fe2O3 (iron oxide), MgO (magnesium oxide), adsorbed water (H2O), bound water (H2O), and others contain about 70.5% by mass, 11.3% by mass, 2.6% by mass, 1.6% by mass, 1.3% by mass, 0.7% by mass, 0.1% by mass, 8.0% by mass, 3.9% by mass, respectively, but of course it is not limited to this composition, and zeolite prepared by varying each component by about 0.1 to 2 parts and totaling 100% can be used. In addition, in the present invention, for example, zeolite such as K(AlSi2O6) can be used.

[0069] According to an embodiment of the present invention, the content ratio (% by mass) of zeolite in the treatment agent is 0.01% by mass or more, 0.05% by mass or more, 0.1% by mass or more, 0.5% by mass or more, 1% by mass or more, 1.5% by mass or more, 2% by mass or more, 3% by mass or more, 3.5% by mass or more, 4% by mass or more, 4.5% by mass or more, 5% by mass or more, 5.5% by mass or more, 6% by mass or more, 6.5% by mass or more, 7% by mass or more, 7.5% by mass or more, or 8% by mass or more. According to an embodiment of the present invention, the content ratio (% by mass) of zeolite in the treatment agent is 40% by mass or less, 30% by mass or less, 25% by mass or less, 20% by mass or less, 15% by mass or less, 13% by mass or less, 12% by mass or less, 10% by mass or less, 9% by mass or less, or 8.5% by mass or less.

[0070] According to an embodiment of the present invention, the content ratio (mass %) of zeolite in the treatment agent is 0.01 to 40 mass %, 0.05 to 30 mass %, 0.1 to 20 mass %, 0.5 to 15 mass %, 1 to 13 mass %, 1.5 to 12 mass %, 2 to 9 mass %, 3 to 9 mass %, or 3.5 to 8.5 mass %. According to an embodiment of the present invention, the content ratio (mass %) of zeolite is 1 to 20 mass %.

[0071] (humic acid) According to an embodiment of the present invention, the treatment agent contains humic acid. Humic acid is the final product formed by the microbial decomposition of plants, etc., and can be the organic part that is not classified as sugars or carbohydrates, proteins, lipids, etc. Humic acid has a strong chelating ability with metal ions, has multiple functional groups, and can be hydrolyzed to produce sugars or amino acids.

[0072] According to an embodiment of the present invention, the average particle size of the material containing humic acid is about 100 nm to 3 mm, about 0.01 to 1 mm, about 100 to 900 μm, about 200 to 800 μm, or about 400 to 600 μm. According to an embodiment of the present invention, in the material containing humic acid, 1 to 15 mass %, 5 to 14 mass %, or 7 to 12 mass % does not pass through a sieve with a sieve hole of 0.6 mm after passing through a sieve with a sieve hole of 42 mm, 15 to 45 mass %, 30 to 43 mass %, or 40 to 42 mass % passes through a sieve with a sieve hole of 0.6 mm and does not pass through a sieve with a sieve hole of 0.3 mm, and 20 to 60 mass %, 35 to 55 mass %, or 46 to 52 mass % passes through a sieve with a sieve hole of 0.03 mm.

[0073] In an embodiment of the present invention, as a method for preparing the material containing humic acid, the method of purchasing commercially available products is preferred.

[0074] According to an embodiment of the present invention, the content ratio (mass %) of the material containing humic acid in the treatment agent is 0.01 mass % or more, 0.05 mass % or more, 0.1 mass % or more, 0.5 mass % or more, 1 mass % or more, 1.5 mass % or more, 3 mass % or more, 4 mass % or more, 5 mass % or more, 6 mass % or more, 6.5 mass % or more, 7 mass % or more, 7.5 mass % or more, 8 mass % or more, 8.5 mass % or more, or 9 mass % or more. According to an embodiment of the present invention, the content ratio (mass %) of the material containing humic acid in the treatment agent is 30 mass % or less, 25 mass % or less, 20 mass % or less, 15 mass % or less, 13 mass % or less, 12 mass % or less, 10 mass % or less, 8 mass % or less, or 7 mass % or less.

[0075] According to an embodiment of the present invention, the content ratio (mass %) of the material containing humic acid in the treatment agent is 0.01 to 30% by mass, 0.05 to 25% by mass, 0.1 to 20% by mass, 3 to 15% by mass, 4 to 13% by mass, or 5 to 12% by mass. According to an embodiment of the present invention, the content ratio (mass %) of the material containing humic acid is 1 to 20% by mass.

[0076] According to an embodiment of the present invention, the treatment agent contains lignin, bentonite, and humic acid. By such a combination, it is possible to more efficiently suppress malodors such as ammonia as the object to be treated.

[0077] (Disodium hydrogen phosphate) According to an embodiment of the present invention, the treatment agent contains disodium hydrogen phosphate. According to an embodiment of the present invention, the average particle size of disodium hydrogen phosphate is about 100 nm to 3 mm, about 0.01 to 1 mm, about 100 to 900 μm, about 200 to 800 μm, or about 400 to 600 μm, but is not limited thereto, and disodium hydrogen phosphate having a size possessed by commercially available products can be appropriately used even if it is outside the above range.

[0078] According to an embodiment of the present invention, the content ratio (mass %) of disodium hydrogen phosphate in the treatment agent is 0.01% by mass or more, 0.05% by mass or more, 0.1% by mass or more, 0.5% by mass or more, 1% by mass or more, 1.5% by mass or more, 3% by mass or more, 4% by mass or more, or 5% by mass or more. According to an embodiment of the present invention, the content ratio (mass %) of disodium hydrogen phosphate in the treatment agent is 30% by mass or less, 25% by mass or less, 20% by mass or less, 15% by mass or less, 13% by mass or less, 12% by mass or less, 10% by mass or less, 8% by mass or less, or 7% by mass or less.

[0079] According to an embodiment of the present invention, the content ratio (mass %) of disodium hydrogen phosphate in the treatment agent is 0.01 to 30% by mass, 0.05 to 25% by mass, 0.1 to 20% by mass, 3 to 15% by mass, 4 to 13% by mass, or 5 to 12% by mass. According to an embodiment of the present invention, the content ratio (mass %) of disodium hydrogen phosphate is 1 to 10% by mass.

[0080] (Sodium dihydrogen phosphate) According to an embodiment of the present invention, the concentration of sodium dihydrogen phosphate is less than 1% by mass. According to an embodiment of the present invention, the treatment agent practically does not contain sodium dihydrogen phosphate.

[0081] (Sodium bicarbonate) According to an embodiment of the present invention, the treatment agent contains sodium bicarbonate. Sodium bicarbonate is a sodium hydrogencarbonate represented by the compositional formula NaHCO3. Sodium bicarbonate can also be used as a food additive and is safe for the human body. Therefore, sodium bicarbonate is suitable in terms of being less likely to cause reagent damage. As a method of preparing sodium bicarbonate, commercially available products can be purchased. For example, industrial-grade sodium bicarbonate manufactured by Tosoh, QINDAOHAIWANGROUPIMP.&EXP.CO., Zichuan Antou Alum Factory, etc. are preferred. According to an embodiment of the present invention, the average particle size of sodium bicarbonate is not particularly limited, preferably 30 to 150 μm, more preferably 80 to 100 μm.

[0082] According to an embodiment of the present invention, the content ratio (mass%) of sodium bicarbonate in the treatment agent is 0.01 mass% or more, 0.05 mass% or more, 0.1 mass% or more, 0.5 mass% or more, 1 mass% or more, 1.5 mass% or more, 2 mass% or more, 3 mass% or more, 3.5 mass% or more, 4 mass% or more, or 4.5 mass% or more. According to an embodiment of the present invention, the content ratio (mass%) of sodium bicarbonate in the treatment agent is 40 mass% or less, 38 mass% or less, 35 mass% or less, 33 mass% or less, 30 mass% or less, 29 mass% or less, 28 mass% or less, 25 mass% or less, 20 mass% or less, 18 mass% or less, 15 mass% or less, 13 mass% or less, 12 mass% or less, 11 mass% or less, or 10 mass% or less.

[0083] According to an embodiment of the present invention, the content ratio (mass%) of sodium bicarbonate in the treatment agent is 0.01 to 40 mass%, 0.05 to 38 mass%, 0.1 to 35 mass%, 0.5 to 30 mass%, 1 to 28 mass%, 1.5 to 25 mass%, 2 to 20 mass%, 3 to 18 mass%, 3.5 to 15 mass%, 4 to 12 mass%, or 4.5 to 10 mass%. According to an embodiment of the present invention, the content ratio (mass%) of sodium bicarbonate in the treatment agent is 1 to 20 mass%.

[0084] (Limonite) According to an embodiment of the present invention, the treatment agent contains limonite.

[0085] The chemical composition of limonite is FeO(OH)·nH2O, but sometimes contains hematite (Fe2O3) or clay minerals, manganese(II) oxide, etc. as impurities. By containing limonite, it is possible to decompose and adsorb sulfur-containing compounds such as mercaptan, methyl mercaptan, and hydrogen sulfide, or fatty acid compounds, which are malodorous components in feces.

[0086] According to one embodiment of the present invention, the content ratio (mass %) of limonite in the treatment agent is 0.01 mass % or more, 0.05 mass % or more, 0.1 mass % or more, 0.5 mass % or more, 1 mass % or more, 1.5 mass % or more, 2 mass % or more, 3 mass % or more, 3.5 mass % or more, 4 mass % or more, or 4.5 mass % or more. According to one embodiment of the present invention, the content ratio (mass %) of limonite in the treatment agent is 40 mass % or less, 38 mass % or less, 35 mass % or less, 30 mass % or less, 28 mass % or less, 25 mass % or less, 20 mass % or less, 18 mass % or less, 15 mass % or less, 13 mass % or less, 12 mass % or less, 10 mass % or less, 5 mass % or less, 2 mass % or less, or less than 1 mass %.

[0087] According to one embodiment of the present invention, the content ratio (mass %) of limonite in the treatment agent is 0.01 to 40 mass %, 0.05 to 38 mass %, 0.1 to 35 mass %, 0.5 to 30 mass %, 1 to 28 mass %, 1.5 to 25 mass %, 2 to 20 mass %, 3 to 18 mass %, 3.5 to 15 mass %, 4 to 12 mass %, or 4.5 to 10 mass %. According to one embodiment of the present invention, in the treatment agent, the concentration of limonite is less than 1 mass %. According to one embodiment of the present invention, the treatment agent practically contains no limonite.

[0088] According to one embodiment of the present invention, the volume average particle diameter (D50) in the particle size distribution measurement of limonite is preferably 0.1 to 200 μm, more preferably 1 to 150 μm, still more preferably 5 to 100 μm, and even more preferably 10 to 50 μm. By being in such a range, the desired effects of the present invention can be efficiently exerted.

[0089] As limonite, it can be freely selected from commercially available products. For example, LMB50, LMB300 (manufactured by Japan Limonite Co., Ltd. etc.) can be cited.

[0090] According to one embodiment of the present invention, the treatment agent is in an air-dried state (a state in which the treatment agent placed in the atmosphere reduces moisture by natural drying and maintains balance with the humidity in the atmosphere).

[0091] <Block-shaped treatment agent> According to an embodiment of the present invention, the treatment agent can be granulated using binders such as water, PVA, cellulose, water-soluble cellulose, sodium alginate, etc. That is, according to an embodiment of the present invention, the treatment agent is a block-shaped treatment agent. In addition, the treatment agent according to an embodiment of the present invention can be formed into a granular treatment agent or a block-shaped treatment agent using the technology of Japanese Patent Application Laid-Open No. 2013-6137 or Re-Published Patent Application No. 2011 / 162244. According to an embodiment of the present invention, the treatment agent contains a lubricant. The lubricant is particularly used to facilitate the feeding of the treatment agent into the mortar of the tablet press when making the block-shaped treatment agent. Therefore, as the type of lubricant, conventionally known types can be appropriately selected or used in combination. For example, esters, silicones, stearic acid esters, calcium stearate, potassium stearate, calcium, zinc, etc. are used. The content of the lubricant is about 0.3 to 5% by mass, about 0.8 to 4.5% by mass, about 0.8 to 3% by mass relative to the total amount of the treatment agent.

[0092] According to an embodiment of the present invention, the average diameter of the treatment agent is 0.01 to 100 mm, 0.1 to 50 mm, 1 to 30 mm, 3 to 20 mm, 5 to 20 mm. In this specification, unless otherwise specified, the "average diameter" refers to the average value obtained by arbitrarily selecting a statistically reliable number (or 10, 100, 200, 300, or 1000) of particles, measuring the longest particle diameter for each particle with a vernier caliper, and adding them up and averaging.

[0093] According to an embodiment of the present invention, the treatment agent is made using a bench-top manual tablet press. In order to make a block-shaped treatment agent using a bench-top manual tablet press (one pestle and one mortar), first, each component to be solidified is put into the pestle with a spoon by hand. After that, the operating rod is manually (hydraulically) pressed down to apply pressure to make each component compact and form a block-shaped treatment agent. In addition, for example, when using a pestle with a small diameter (7 mm: upper and lower circular plate type), if the diameter is small, since a higher pressure is applied per unit area, even components that are difficult to solidify tend to be formed. On the other hand, for example, when using a pestle with a large diameter (15 mm: upper and lower flat plate type), if the diameter is large, since the pressure per unit area becomes smaller, it is not favorable for components that are difficult to solidify, but corresponding to the large diameter, it is favorable for feeding the pestle and the productivity is improved.

[0094] According to an embodiment of the present invention, a treatment agent is produced using a continuous tablet press. The continuous tablet press may or may not be a direct punching type, but a direct punching type with improved productivity is preferably adopted in view of saving the trouble of pretreatment. In addition, in order to facilitate the feeding of the fine powder component, a wetting agent is preferably added. On the other hand, in the case of pretreatment, for example, a block-shaped treatment agent can be produced by pressing a material in which a binder is mixed in a material obtained by granulating fine powder by rolling under a large pressure using a roll compactor. In view of mass production, for example, a tablet press (model AP18-SS, etc.) manufactured by Tatekobo Co., Ltd. is preferably used. The diameter of the pestle at this time is about 13 mm, and the number of pestles is about 18. If such a tablet press is used, it is preferable because production can be carried out by preparing the raw materials in a desired ratio, mixing them, putting the mixed raw materials into the hopper of the tablet press, and performing rotary tableting with the tablet press.

[0095] According to an embodiment of the present invention, a treatment agent is produced using a continuous rotary tablet press. As described above, the method for producing the treatment agent (block-shaped treatment agent) is not particularly limited. It can be produced by mixing the components constituting the treatment agent in any order, or by mixing the desired components containing a binder while pressing with a tablet press.

[0096] (Binder) According to an embodiment of the present invention, the binder is preferably a cellulose-based binder. According to an embodiment of the present invention, it has the function of binding part or all of the components contained in the treatment agent.

[0097] According to an embodiment of the present invention, the binder can be prepared by purchasing commercially available products. PH-102, TG-101, ST-02, TG-101 manufactured by Asahi Kasei Chemicals Corporation, PVPK-15, PVPK-30, PVPK-90 (polyvinylpyrrolidone) manufactured by Higuchi Shokai Co., Ltd., KC series (KCflockW-50S, W-50, W-100 / 100G, W-200 / 200G, W-250, W-300G, W-400G) manufactured by Nippon Paper Chemicals Co., Ltd., CEOLUS series (CEOLUS K2) manufactured by Asahi Kasei Chemicals Corporation, etc. are suitably used as commercially available products.

[0098] The main function of the binder is to help solidification. Therefore, the smaller the amount, the better. According to one embodiment of the present invention, the content ratio (mass %) of the binder in the treatment agent is 5 mass % or more, 10 mass % or more, 15 mass % or more, 20 mass % or more, or 25 mass % or more. According to one embodiment of the present invention, the content ratio (mass %) of the binder in the treatment agent is 60 mass % or less, 55 mass % or less, 50 mass % or less, or 45 mass % or less. According to one embodiment of the present invention, the content ratio (mass %) of the binder in the treatment agent is 10 to 50 mass %.

[0099] According to one embodiment of the present invention, the treatment agent is not in a block form. According to one embodiment of the present invention, the treatment agent may be in the form of a mixture that is simply mixed without applying pressure or the like to the components constituting the treatment agent. According to one embodiment of the present invention, the treatment agent does not substantially contain an adhesive having a function of bonding a part or all of the components constituting the treatment agent. Furthermore, in this specification, the expression "does not substantially contain" includes the concept that the treatment agent contains less than 0.005 mass % of the component in addition to the concept that the component is completely absent.

[0100] According to one embodiment of the present invention, the block-shaped treatment agent is in an air-dried state (a state in which the treatment agent placed in the atmosphere reduces moisture through natural drying and maintains a balance with the humidity in the atmosphere).

[0101] <Treatment with treatment agent> The specific method of treatment is not particularly limited. According to one embodiment of the present invention, a method of contacting the waste liquid with the treatment agent is preferred. According to one embodiment of the present invention, a method of adding a treatment agent to the waste liquid can be cited. According to one embodiment of the present invention, a method of adding waste liquid to a treatment agent can be cited. According to one embodiment of the present invention, the treatment agent is pre-configured in a bottle storing waste liquid discharged from a person through surgery (e.g., endoscopy). The waste liquid discharged by suction or the like is introduced into a bottle pre-configured with the treatment agent of the present invention to treat the waste liquid.

[0102] For example, in endoscopy, waste liquids (excrement, blood, body fluids, etc.) from the digestive system (stomach, rectum, large intestine, small intestine, etc.) after the examination are discharged, and the waste liquids are provided for sewage treatment. In addition, in a hospital, waste liquids such as urine of inpatients are also provided for sewage treatment. These waste liquids sometimes contain spore-forming bacteria such as the genus Bacillus or the genus Clostridium. Spore-forming bacteria are representatives of opportunistic infectious pathogens. Spore-forming bacteria are heat-resistant bacteria that can withstand heat above 100 °C. In addition, if the nutrients are insufficient or the environment deteriorates, spores will be formed inside the bacteria. Since the spores are not only tolerant to heat but also to dryness and disinfectants, they can survive in a harsh environment until the environment becomes suitable for growth. And if the growth environment such as moisture, temperature, and nutrients is perfect, they will germinate into vegetative cells and proliferate. Therefore, spore-forming bacteria require special attention in the control of nosocomial infections. The treatment agent of the present invention can inhibit or hinder the spore germination or proliferation of spore-forming bacteria by contacting with such waste liquids. Therefore, it is particularly useful in hospitals that need to treat a large amount of patient waste liquids. Here, although the reason why the treatment agent of the present invention exerts an inhibitory or obstructive effect on the spore germination or proliferation of spore-forming bacteria is unknown, the following is speculated. In addition, the present invention is not limited to the following speculation. The treatment agent of the present invention contains slaked lime and pepper. Among them, due to the presence of slaked lime, the waste liquid becomes alkaline. Therefore, the spore coats (outer spore coat, inner spore coat) of spore-forming bacteria placed in an alkaline environment become soft, and substances are easily invaded from the outside. Therefore, the pepper or zinc oxide (when further contained) in the treatment agent easily acts directly on the nucleus, thereby effectively inhibiting or hindering the spore germination or the proliferation (growth) of bacteria.

[0103] That is, the treatment agent of the present invention is used to inhibit or hinder the spore germination or proliferation of spore-forming bacteria. In addition, the present invention also provides a method for inhibiting or hindering the spore germination or proliferation of spore-forming bacteria, which has a step of contacting the waste liquid with the treatment agent of the present invention. Here, as spore-forming bacteria, there are well-known spore-forming bacteria such as the genus Amphibacillus, the genus Bacillus, the genus Clostridium, and the genus Sporosarcina. Among them, the treatment agent of the present invention exerts excellent inhibitory or obstructive ability on the spore germination or proliferation of the genus Clostridium, particularly Clostridioides difficile.

[0104] According to one embodiment of the present invention, the amount of the treatment agent relative to the object to be treated (e.g., waste liquid discharged during endoscopy: about 1000 mL to about 4000 mL) can be appropriately adjusted as needed. As a standard, it is 1 to 1000 g, 2 to 900 g, 3 to 800 g, 5 to 750 g, 10 to 700 g, 20 to 650 g, or 30 to 600 g. According to one embodiment of the present invention, after bringing the object to be treated into contact with the treatment agent (and then mixing as needed), for example, it can be left standing for 5 minutes to 30 days, 120 minutes to 20 days, 300 minutes to 10 days, 200 minutes to 5 days, 400 minutes to 3 days, or 500 minutes to 2 days. The treatment agent according to the present invention also has the effect of suppressing the odor from the object to be treated for a long time.

[0105] In this embodiment, the treatment agent may further contain other components. Here, as the other components, there are antibacterial agents. Here, when the treatment agent further contains an antibacterial agent, the antibacterial agent is not particularly limited. For example, inorganic antibacterial agents such as silver and copper, natural antibacterial agents such as chitin, chitosan, allyl isothiocyanate, hinokitiol, and limonene, and antibacterial agents such as penicillins and macrolides can be cited. When the treatment agent further contains an antibacterial agent, the amount of the antibacterial agent is not particularly limited and can be appropriately selected according to the desired effect of inhibiting or hindering spore germination or proliferation.

[0106] [Examples] <Preparation of artificial waste liquid (control group (i))> Dissolve 4 g of soy protein hydrolyzate (polypeptone), 0.8 g of garlic puree, and 0.2 g of urea in 1 L of pure water. Add 1.0 g-wet black soil to 25 mL of this solution as the control group (i).

[0107] <Production of control groups (ii) and (iii)> Add 1 tablet (0.72 g) of control treatment agent 1 to the control group (i) as the control group (ii), and add 0.72 g of control treatment agent 2 to the control group (i) as the control group (iii).

[0108] (Production of control treatment agent 1) Control treatment agent 1 (average diameter: 15 mm, average thickness: 5 mm) was obtained by placing the following components in a mortar of a tableting machine (manufactured by Kikusui Seisakusho Co., Ltd.) and pressing them with a pressure of 40 kN to obtain 70 tablets of the treatment agent. In addition, the pestle used was a flat type with a diameter of 15 mm.

[0109] [Table 1]

[0110] KC200 (KC flock): Manufactured by Nippon Paper Industries, average particle size 32 μm Sodium bicarbonate: Manufactured by Tosoh Corporation, average particle size 90 μm Disodium hydrogen phosphate: Manufactured by MITEJIMA Chemical, average particle size 90 μm Slaked lime: Manufactured by Ube Materials Co., Ltd., passing through 100 mesh Zeolite: ZEOFILL W1, volume average particle size (D50): 13 μm Zinc oxide: Zinc oxide type 1, manufactured by hakusuitech Co., Ltd., average particle size 0.6 μm Water-absorbing polymer (SANFRESH ST-573): Average particle size: 380 μm (about 1 mass% over 850 μm, over 106 μm and 850 μm or less Calcium stearate: sunace SAK-CS-P, average particle size 7 μm (containing some particles over 50 μm). (Preparation of control treatment agent 2) Mix the respective components constituting the treatment agent according to the composition shown in the following table to prepare 100 g of the treatment agent.

[0111] [Table 2]

[0112] Limonite: LMB-50, volume average particle size (D50): 22 μm Lignin: SanX P-202, average particle size: 60 μm Bentonite: MOISTNITE S, average particle size: 139 μm Slaked lime: Manufactured by Ube Materials Co., Ltd.: Passing through 100 mesh Water-absorbing polymer: Polyacrylic acid polymer, SANFRESH ST-250, average particle size: 380 μm (about 1 mass% over 850 μm, 89 mass% over 106 μm and 850 μm or less, about 10 mass% 106 μm or less).

[0113] <Addition of various agents> Add the following various agents, etc. to the control group (ii) and the control group (iii) in the following amounts and concentrations.

[0114] [Table 3]

[0115] * Add various agents to 25 mL of artificial waste liquid. Therefore, only the actual addition amounts of the various agents of the disclosed concentrations can be converted according to the above concentrations.

[0116] First, the results of the measurement of the odor intensity of the experiment based on the control group (ii) are shown in Table 5.

[0117] In addition, the odor intensity is judged by adding and averaging the scores given by multiple (3 people) who passed the odor judge selection test according to the following criteria.

[0118] [Table 4]

[0119] [Table 5-1]

[0120] [Table 5-2]

[0121] Observing the change of odor intensity in Table 5, the control group (i) changed around odor intensity 3.5 from the first day to the eleventh day. The control group (ii) showed a significant effect of odor intensity 2 on the first day, but the intensity gradually increased, was the same as the control group (i) on the fifth day, and was the highest among all systems on the eighth day.

[0122] In the systems where various agents were added to the control group (ii), the effects of CaO or iron oxide added for the purpose of improving the reducing environment where malodorous substances are easily generated were low, worse than or equivalent to the control group (ii). The systems added with activated carbon changed below about odor intensity 0.5 of the control group (ii) until the eighth day, and were considered to have a certain effect, but mildewed and emitted an unpleasant smell on the eighth day. Therefore, the test of the system added with activated carbon was stopped. In addition, there were experimental groups such as those where the discomfort increased due to the change in the odor quality caused by the agent itself or mildew. The systems added with copper salts, silver salts, alum, chlorinating agents or bactericides for the purpose of sterilization all inhibited fecal odor and putrid odor more than the control group (ii), but there were also cases like chlorinating agents where the odor intensity became high due to the strong odor of the agent, and the results were not sufficient.

[0123] In addition, regarding the odor quality, fecal odor or the odor of a flush toilet was felt in the control group (i) from around the fourth day, and although the odor intensity of the control group (ii) was low, the odor of a flush toilet was felt from the same period.

[0124] The system added with CaO or silver salt has little difference from the control group (ii) in terms of the change in odor quality. The system added with iron oxide or alum inhibited the odor of the extraction toilet for several days, but then emitted a similar odor. In addition, although the system added with activated carbon or copper salt slightly inhibited the odor of the extraction toilet, it was considered not good because other odors or mildew were emitted. Although the system added with dichloroisocyanuric acid could hardly feel the odor of the extraction toilet, a strong chlorine odor or burnt odor could be felt.

[0125] On the other hand, regarding the state during use, in the control group (ii), water began to flow upward on the fourth day, and on the sixth day, it was divided into three layers and water was observed in the middle layer. In contrast, in the system added with CaO, it was divided into three layers on the fourth day and the water content was also high. It can be considered that this is because calcium coordinates to the superabsorbent polymer (water-absorbing polymer), resulting in a decrease in the water absorption amount. The same phenomenon can also be observed in the system added with copper salt. In other systems, no significant difference from the control group was observed in terms of water retention.

[0126] Next, the odor intensity measurement results of the control treatment agent 2 are shown in Table 7.

[0127] [Table 6]

[0128] * Various agents were added to 25 mL of artificial waste liquid. Therefore, only the actual addition amounts of various agents with the disclosed concentrations can be converted according to the above concentrations.

[0129] [Table 7-1]

[0130] [Table 7-2]

[0131] The control treatment agent 2 (control group (iii)) only inhibited the odor second only to activated carbon in the whole on the first day, but the odor intensity increased significantly on the fourth and fifth days. It may be because the odor was strong. Although it decreased slightly after the eighth day, it was considered that the control treatment agent 2 (control group (iii)) had a low effect of inhibiting the generation of malodor in the long term.

[0132] In the systems with various agents added to the control group (iii), except for the systems added with CaO or zeolite, generally a lower odor intensity was shown. Among them, the silver salt addition system, activated carbon addition system or cationic surfactant addition system (fungicide addition system) showed better results.

[0133] However, regarding odor quality, in the control group (iii), strong fecal odor, extraction toilet odor, and irritation were felt on the fourth day. In the systems added with zeolite, CaO, iron oxide, activated carbon, copper salt, silver salt, or alum, although there were differences in intensity, extraction toilet odor was felt starting from the same period.

[0134] In the system added with dichloroisocyanuric acid, pharmaceutical odor was continuously felt at a certain intensity. In the system added with benzalkonium chloride, garlic odor persisted for a long time. Although the decomposition of organic matter was inhibited and the generation of fecal odor was also inhibited, toilet-related odor was emitted on the eleventh day.

[0135] Regarding the state during use, in the system added with CaO, there was almost no water retention and it was in a state of high moisture. The other systems had no significant differences from the control group (iii).

[0136] In the above tests, since the water absorption effect was weakened in the system added with CaO and it had no effect on odor, further research was ended. Since the system added with iron oxide only had a slightly effective degree, further research was ended. The effects of copper salt and silver were the same, but since it hindered the water-absorbing resin, further research was ended.

[0137] The above was the first test. Then, as the second test, for the systems added with silver salt, alum, dichloroisocyanuric acid, or benzalkonium chloride, the effects were confirmed by changing the concentration. In addition, as the agents added to the control group (ii), the following agents (single types) were tested individually, namely, CMC (sodium carboxymethyl cellulose) paste predicted to have the effect of increasing viscosity to inhibit the movement of substances; sodium chloride predicted to have the effect of increasing the salt concentration to reduce the activity of microorganisms; soluble iron oxide salt; benzethonium chloride, a cationic surfactant similar to benzalkonium chloride; and sodium percarbonate that generates hydrogen peroxide in water. Further, for the combinations of benzalkonium chloride and activated carbon, sodium chloride and activated carbon, sodium percarbonate and activated carbon, sodium percarbonate and benzalkonium chloride, and sodium percarbonate and silver salt, the effects as the agents added to the control group (ii) were confirmed (compound types).

[0138] The conditions for these second odor inhibition tests are shown in the following table.

[0139] [Table 8]

[0140] * Various agents were added to 25 mL of artificial waste liquid. Therefore, the actual addition amounts of various agents with only the concentrations disclosed can be converted according to the above concentrations.

[0141] The comfort level is judged by multiple (3 people) who passed the test in the odor determination experiment selected by the odor judges scoring according to the following criteria and calculating the average of the added scores.

[0142] [Table 9]

[0143] ※Negative evaluations are accompanied by fecal odor or putrid odor.

[0144] [Table 10-1]

[0145] [Table 10-2]

[0146] In the control group (ii), the odor of the extraction toilet was stronger from the third day to the seventh day. This might be because the odor components related to the toilet volatilized during this period, and then the odor of vegetable putrefaction was felt.

[0147] In the addition systems of silver salt, alum, sodium chloride, or ferric chloride, the odor of the extraction toilet was felt approximately from the third day, and moldy smell and odor changes occurred around the seventh to eleventh day, so the experiment was stopped.

[0148] In the system with CMC paste added, although there was an odor of plastic or rubber, the odor of the extraction toilet was hardly felt until about the eighth day, but then the odor of the extraction toilet and putrid odor became stronger.

[0149] In the addition systems of benzalkonium chloride or benzethonium chloride, the drug odor was always felt, but the odor of the extraction toilet was more inhibited, and this effect was higher in the system with benzethonium chloride added. In the system with sodium percarbonate added, although a unique and uncomfortable drug odor was felt, the odor of the extraction toilet itself was more inhibited until about the second week.

[0150] [Table 11]

[0151] In the systems with combined additives, moldy situations were also common during the experiment, and no special effect of combination was found in this system.

[0152] The odor intensity is an index regarding the strength of the odor. There are cases where one does not feel uncomfortable even though the odor is strong, and there are also cases where one feels uncomfortable even though the odor is weak. Therefore, the research focuses on the comfort level of the odor and continues.

[0153] For the control group (ii), as various agents of the natural type, agents containing tea (100% green tea leaves), agents containing perilla, agents containing chili peppers, agents containing black pepper, agents containing houttuynia cordata, agents containing powdered mustard, and agents containing powdered wasabi were respectively prepared, and the comfort level of the odor was evaluated in the same manner as above. The amounts added to the control group (ii) were all 0.1 g.

[0154] [Table 12]

[0155] As a result, in terms of the comfort level, the system containing pepper was the best, with a level where discomfort was hardly felt for about 10 days. Looking at the odor quality (smell quality), in the system containing pepper where the discomfort level did not increase, it was mainly considered to be the peculiar smell of pepper. The composition of the system containing pepper is summarized below.

[0156] [Table 13]

[0157] In addition, in the above table, if the content ratios of the respective components are converted after removing the binder (KC200 (KC flock)), they are as follows.

[0158] [Table 14]

[0159] Next, further research was conducted to see if there was a better system than pepper. Specifically, since the control group (ii) contained slaked lime (alkali component), research was carried out on whether adding more alkali could inhibit putrefaction and thus suppress malodor, and whether adding potassium iodide to react with organic substances to act as an iodine agent to play a bactericidal role could suppress malodor. Specifically, for the control group (ii), as various agents, agents containing sodium sesquicarbonate, agents containing sodium bicarbonate, and agents containing potassium iodide were respectively prepared, and the comfort level of the odor was evaluated in the same manner as above. The amounts of the agents added to the control group (ii) were all 0.1 g.

[0160] [Table 15]

[0161] As shown in Table 15, these were the same as or lower than the control group (ii) in terms of the comfort level, and no effect was found. There was also not much difference in the odor quality.

[0162] Next, with the aim of reducing the amount of malodor volatilized by decreasing the mobility of malodor components and the like in the liquid caused by the increase in viscosity, an experiment of adding a thickener having a thickening effect was conducted. Specifically, for the control group (ii), as various agents, an agent containing hiMETOLOSE, an agent containing PVA, and an agent containing starch were prepared respectively, and the comfort level of the odor was evaluated in the same manner as above. For the amounts of the agents added to the control group (ii), 0.1 g of hiMETOLOSE and starch, and 0.1 ml of PVA were used.

[0163] [Table 16]

[0164] In this way, the expected results were not obtained.

[0165] Next, with the aim of the malodor suppression effect of a method of reducing the viable cell count such as a surfactant, experiments were conducted using various surfactants. Specifically, for the control group (ii), as various agents, an agent containing 0.1 g of Triton X100 (Kishida Chemical), a representative nonionic surfactant, an agent containing 0.1 g of soap (powdered a general commercially available fatty acid ester soap), and agents containing two cationic surfactant samples (CATION G50: benzalkonium chloride solution; OSMORINDA-50: didodecyldimethylammonium adipate) were used respectively. In addition, the two cationic surfactant samples were used at the following various concentrations. In addition, since various surfactants were added to 25 mL of artificial waste liquid, the actual addition amounts could be converted according to the above concentrations.

[0166] [Table 17]

[0167] Judging from the comfort level of the test results, the system containing Triton X and DA-50 at 300 mg / L showed slightly better results than the control group (ii). When comparing the systems containing G-50 or DA-50 at 100 mg / L, the system containing DA-50 was slightly better. In addition, benzalkonium chloride solution is known to be used as a finger germicide and a disinfectant for polluted environments.

[0168] Based on the above results so far, it can be seen that the result of "pepper" is the most excellent in terms of the malodor reduction effect.

[0169] Therefore, the components of the following composition containing pepper were placed in the mortar of a tabletop tablet press (manufactured by Kikusui Seisakusho Co., Ltd.), and a pressure of 40 kN was applied for tableting to obtain 50 g (70 tablets) each of the block treatment agents KS-22-α1, KS-22-α2, and KS-22-α3. Additionally, 50 g (70 tablets) of tab22 without pepper (average diameter: 15 mm, average thickness: 5 mm) was obtained. Furthermore, the pestle used had a flat upper and lower plate type with a diameter of 15 mm.

[0170] [Table 18]

[0171] In addition, in Table 18 above, if the binder (KC200 (KC flock)) is removed and the content ratios of the respective components are converted, they are as follows.

[0172] [Table 19]

[0173] [Table 20]

[0174] In addition, in Table 20 above, if the binder (KC200 (KC flock)) is removed and the content ratios of the respective components are converted, they are as follows.

[0175] [Table 21]

[0176] [Table 22]

[0177] In addition, in Table 22 above, if the binder (KC200 (KC flock)) is removed and the content ratios of the respective components are converted, they are as follows.

[0178] [Table 23]

[0179] [Table 24]

[0180] In the above tables KC200 (KC flock): Manufactured by Nippon Paper Industries, average particle size 32 μm Water-absorbing polymer (SANFRESH ST-573): Average particle size: 380 μm (about 1 mass% over 850 μm, 89 mass% over 106 μm and 850 μm or less, about 10 mass% 106 μm or less) Lignin: Manufactured by Nippon Paper Industries, SanX P-202, average particle size: 60 μm Slaked lime: Manufactured by Ube Materials Co., Ltd., passing through 100 mesh KUNIPIA-F average particle size: 139 μm Humic acid: Manufactured by pic-bio, Canadian Humic (9% passing through 42 mm - not passing through 0.6 mm, 41% passing through 0.6 mm - not passing through 0.3 mm, 49% passing through 0.03 mm -) Zinc oxide type 1: Manufactured by hakusuitech, average particle size 0.6 μm Black pepper: Ajinomoto Foods Co., Ltd., Table Pepper Zeolite ZEOFILLW1, volume average particle size (D50): 13 μm Calcium stearate: sunace, SAK-CS-P average particle size 7 μm (containing some particles over 50 μm).

[0181] Then, add 1 tablet (0.72 g) of each of the above-mentioned block-shaped treatment agents to the control group (i).

[0182] Regarding these, in the same way as the previous experiment, the comfort level was measured by multiple (3 people) who passed the odor judge selection test.

[0183] [Table 25]

[0184] <Preparation of simulated feces> Next, as the simulated feces used in the experiment, simulated feces were prepared by sequentially adding fatty acids, indole, and skatole in amounts that each contribute to odor to stone powder clay with a texture and specific gravity similar to feces and mixing them. The preparation concentrations are shown in the following table.

[0185] [Table 26]

[0186] * Adjusting the concentration means the added weight of each component relative to 1 kg of simulated feces In the experiment, 65 g of simulated feces was placed in a plastic bag, and after adding the specified amounts (50 g) of control treatment agent 1, KS-22-α1, and KS-22-α1 powder type + silver salt (0.5 mass% silver nitrate was added relative to the total mass of KS-22α1 - powder type (unpressed)), 200 mL of pure water was added and immediately placed in a 17 L container. In this way, evaluations of the control group (without adding treatment agent), control treatment agent 1, KS-22-α1, and KS-22-α1 powder type + silver salt were carried out.

[0187] <Test Results> The measurement results of the concentrations of n-butyric acid, n-valeric acid, isovaleric acid, indole, and skatole, and the inhibition rates of the control group on odor substances are shown in the following table.

[0188] (n-Butyric Acid) For n-butyric acid, the volatile concentration of the control group (adding 200 mL of pure water to the simulated feces) was 0.34 ppm at the 4th hour and about 0.7 ppm after the third day. In contrast, the concentration of control treatment agent 1 was 0.15 ppm at the 4th hour, 0.07 ppm on the third day, and about 0.04 ppm after the first week. In the KS-22-α1 and KS-22-α1 powder type + silver salt systems, the concentration was below 0.03 ppm at the 4th hour and below about 0.01 ppm after the first day, showing a relatively low level. From the perspective of the inhibition rate, the KS-22-α1 powder type + silver salt system showed an inhibition rate of more than 98% after the first day.

[0189] The control treatment agent 1 system had an inhibition rate of about 90% or more after the first day, but the KS-22-α1 system showed a performance with an inhibition rate about 10% higher. Although it seems to be only about 10%, this means whether it is 1 / 10 or 1 / 50 of the odor of the control group. Considering that the human response to odor is exponential and the odor intensity and concentration standards of the anti-odor law, for n-butyric acid, it is considered that an improvement in the sensory evaluation (odor intensity) by about one level has been achieved.

[0190] (n-Valeric Acid) For n-valeric acid, the concentration of the control group was 0.4 ppm at the 4th hour and about 1.3 ppm after the first day. In contrast, the concentration of control treatment agent 1 was 0.08 ppm at the 4th hour and below 0.03 ppm after the first day, showing a relatively low level. In KS-22-α1 and KS-22-α1 powder type + silver salt, the concentration was below about 0.01 ppm starting from the 4th hour, showing a higher performance than control treatment agent 1. From the inhibition rate relative to the control group, the inhibition rate of control treatment agent 1 was 80% at the 4th hour, while that of KS-22-α1 and KS-22-α1 powder type + silver salt was more than 95%. After the first day, the inhibition rate of control treatment agent 1 was in the range of 97 - 99%, while the inhibition rate of KS-22-α1 and KS-22-α1 powder type + silver salt showed more than 99%.

[0191] (Isovaleric Acid) For isovaleric acid, a similar tendency to valeric acid was also shown. In the control group, it was 0.33 ppm at the 4th hour and about 1.1 ppm after the first day. For control treatment agent 1, it was 0.04 ppm at the 4th hour and below 0.01 ppm after the first day. For KS-22-α1 and KS-22-α1 powder type + silver salt, it was below 0.01 ppm starting from the 4th hour. Even from the perspective of the inhibition rate, a similar tendency to n-valeric acid was shown.

[0192] From the measurement results of these three fatty acids, it was shown that KS-22-α1 could rapidly inhibit the volatilization of acidic fecal odor gases in a short time. In addition, it can be said that it remained at a level higher than that of previous products in terms of these components for two consecutive weeks and continuously inhibited volatilization.

[0193] (Indole, skatole) Regarding the different properties of chemical substances, for indole and skatole, which are representative fecal odor components, the control group also showed a trend of gradually increasing volatilization concentration. The initial concentration of indole was 0.017 ppm, and it was 0.090 ppm in the second week. In addition, the initial concentration of skatole was 0.005 ppm, and it was 0.029 ppm in the second week.

[0194] In control treatment agent 1, although the concentration decreased compared to the control group, for indole it was 0.010 - 0.027 ppm, and for skatole it was 0.004 - 0.016 ppm, showing a slow trend of increasing concentration until the first week or the second week. In KS-22-α1 and KS-22-α1 powder type + silver salt, for indole it was 0.002 - 0.010 ppm, and for skatole it was 0.001 - 0.003 ppm, and the volatilization concentration was significantly inhibited lower compared to the control group or control treatment agent 1.

[0195] From the perspective of the inhibition rate, the initial inhibition rate of indole was 40%, and it was 60 - 70% after the first day. The variation of skatole was relatively large, but it changed between 10 - 50%, and the inhibition effect was low. Especially skatole is a representative substance of fecal odor, and as a result, the inhibition rate of the volatilization of this substance was not sufficient.

[0196] On the other hand, in KS-22-α1 and KS-22-α1 powder type + silver salt, at the 4th hour, the inhibition rates of both indole and skatole were about 75%, and then increased slightly. For KS-22-α1, it was 80 - 90%, and for KS-22-α1 powder type + silver salt, it was above 90%.

[0197] In control treatment agent 1, the inhibition effect on indole and skatole was low. Although sometimes it showed a volatilization concentration higher than that of the control group, in KS-22-α1, it could be inhibited at a high level of about 80% or more. From this, it can be considered that the odor intensity caused by indole and skatole was also reduced by about one level.

[0198] [Table 27] n-Butyric acid (concentration in gas)

[0199] [Table 28] n-Butyric acid (inhibition rate)

[0200] [Table 29] n-Valeric acid (concentration in gas)

[0201] [Table 30] n-Valeric acid (inhibition rate)

[0202] [Table 31] Isovaleric acid (concentration in gas)

[0203] [Table 32] Isovaleric acid (inhibition rate)

[0204] [Table 33] Indole (concentration in gas)

[0205] [Table 34] Indole (inhibition rate)

[0206] [Table 35] Skatole (concentration in gas)

[0207] [Table 36] Skatole (inhibition rate)

[0208] It was confirmed that the control treatment agent 1 was effective against the fatty acids contained in fecal odor. On the other hand, the effects on alkaline compounds such as ammonia, indole, and skatole were low, and depending on the situation, the odor substances might increase compared with the case where the control treatment agent 1 was not used.

[0209] In addition, regarding the measurement results of the concentrations of n-butyric acid, n-valeric acid, isovaleric acid, indole, and skatole and the inhibition rates of the control group on odor substances, the results after 24 hours and after one week are summarized as follows.

[0210] [Table 37]

[0211] Summarizing the above test results, it was found that as the basic properties of the treatment agent containing slaked lime and pepper, a significant improvement in indole and skatole, which are the targets, was achieved in terms of the volatilization concentration. Even for Control Treatment Agent 1, there was a further improvement in fatty acids with good properties.

[0212] Next, in order to confirm the combined effect of slaked lime and pepper, the types of constituent components were reduced and studied.

[0213] Specifically, the following components were added to the control group (i), and the degree of comfort was judged in the same manner as above.

[0214] [Table 38]

[0215] [Table 39]

[0216] [Table 40]

[0217] [Table 41]

[0218] [Table 42]

[0219] [Table 43]

[0220] From the above results, it can be seen that the combination of slaked lime and pepper shows a significant or different effect.

[0221] Then, the antibacterial / bactericidal effects were evaluated for Samples A to C as follows.

[0222] <Antibacterial / Bactericidal Effect Evaluation> (Sample Preparation) Each component having the following composition was uniformly mixed to prepare Samples A to C.

[0223] [Table 44] Sample A

[0224] In the above table Lignin: Manufactured by Nippon Paper Industries, SanX P-202, average particle size: 60 μm Slaked lime: Manufactured by Ube Materials Co., Ltd.: Passing through 100 mesh KUNIPIA-F: Average particle size: 139 μm Humic acid: Manufactured by pic-bio, CanadianHumic (9% passed through 42 mm and not through 0.6 mm, 41% passed through 0.6 mm and not through 0.3 mm, 49% passed through 0.03 mm -) Zinc oxide, first type: Manufactured by hakusuitech, average particle size 0.6 μm Black pepper: Manufactured by Ajinomoto Foods Co., Ltd., TablePepper Zeolite: ZEOFILLW1, volume average particle size (D50): 13 μm [Table 45] Specimen B

[0225] Specimen C

[0226] In the above table KC200 (KC flock): Manufactured by Nippon Paper Industries, average particle size 32 μm Sodium bicarbonate: Manufactured by Tosoh Corporation, average particle size 90 μm Disodium hydrogen phosphate: Manufactured by MITEJIMA Chemical, average particle size 90 μm Slaked lime: Manufactured by Ube Materials Co., Ltd., passing through 100 mesh Zeolite: ZEOFILL W1, volume average particle size (D50): 13 μm Zinc oxide, first type: Manufactured by hakusuitech, average particle size 0.6 μm Water-absorbing polymer (SANFRESH ST-573): Average particle size: 380 μm (about 1 mass% exceeding 850 μm, exceeding 106 μm and below 850 μm Calcium stearate: sunace SAK-CS-P, average particle size 7 μm (containing some particles above 50 μm). (Strain) As the objects for measuring antibacterial / bactericidal effects, the following three types of bacteria were selected: Escherichia coli, Vibrio cholerae, and Clostridioides difficile. Escherichia coli is a facultative anaerobic Gram-negative bacillus and is the most frequently detected in hospital examination rooms. In addition, Vibrio cholerae is also a Gram-negative bacillus like Escherichia coli and is a bacterium that is often feared to spread in a low-hygiene environment during disasters. Clostridioides difficile is a Gram-positive bacillus and a representative of opportunistic infectious pathogens, and it forms spores, showing tolerance to various sterilization and disinfection methods, thus requiring special attention in nosocomial infection control. The following five strains belonging to these three species were used for measurement.

[0227] ・ Escherichia coli: Standard strain ATCC25922 Clinical isolate (2022 1-1110, blood isolate) ・ Vibrio cholerae: Clinical isolate 1 (2009 7-1320, pus isolate) Clinical isolate 2 (2010 8-1057, fecal isolate) ・ Clostridioides difficile: Clinical isolate (2021 8-68, fecal isolate) In addition, the above clinical isolates were obtained and maintained from non-specific patients at the Medtec・Link Center of the Affiliated Hospital of Chiba University School of Medicine. The above clinical isolates are not novel microorganisms. Therefore, they are not deposited in a depository institution. However, the applicant of the present invention intends to sell the clinical isolates of the present invention to a third party on the condition of complying with the relevant laws, provided that the three articles of Article 27 of the Implementing Regulations of the Japanese Patent Law are met.

[0228] (Preparation of bacterial samples) ・ Clostridioides difficile: For Clostridioides difficile, the sterilized raw food was autoclaved, and the sterilized raw food with dissolved oxygen removed was used to prepare a test bacterial solution with an McFarland (Mcf) turbidity of 0.5. Then, 30 mg of each of the above-prepared specimens A to C was placed in a 1.5 mL microtube, and 1 mL of the test bacterial solution was added to each and mixed. It was allowed to stand at room temperature (25 °C; the same below) for the action time shown in Table 45 below (30 minutes or 24 hours) to prepare a test bacterial solution. In addition, the McFarland turbidity method (Mcf) is a method for estimating the viable cell number concentration of a bacterial solution based on turbidity. Mcf 0.5 corresponds to 1×10 8 CFU / mL for spore-forming bacteria. At this time, CFU (colony-forming unit) is the number of colonies formed when inoculated onto a solid medium for bacterial growth, indicating the number of proliferable microbial cells contained in the inoculated microorganisms.

[0229] After standing at room temperature for the specified time (30 minutes or 24 hours), the test bacterial solution was mixed again and centrifuged at 3,000 rpm for 10 minutes to separate the supernatant. 10 μL of this supernatant was collected using a large pipette and inoculated onto the medium by a semi-quantitative method using an inoculation loop, and cultured in an anaerobic environment (H2 (10%): N2 (10%): CO2 (80%)) at 35 °C (anaerobic culture for 48 hours. In addition, for the control bacterial solution without the addition of the specimen, 10 μL was collected immediately after preparing the test bacterial solution using a large pipette, inoculated onto the medium by a semi-quantitative method using an inoculation loop, and cultured in an anaerobic environment (H2 (10%): N2 (10%): CO2 (80%)) at 35 °C (anaerobic culture) for 48 hours. In addition, the culture was carried out in AneroColumbia RS blood agar medium (RS medium) (manufactured by Becton Dickinson Japan Co., Ltd.). In addition, each test was performed in duplicate.

[0230] When comparing the substance obtained by allowing specimen A to act on the test bacterial solution for 30 minutes and culturing it with the control bacterial solution, a decrease in the number of bacteria was found (see Figure 1 ). Therefore, in order to numerically represent the decrease in the number of bacteria, additional culture measurements for calculating the number of bacteria were carried out by the following method.

[0231] Similarly, freshly prepared control bacterial solutions, as well as control and test bacterial solutions that had been left standing at room temperature for 30 minutes and 24 hours, were prepared. After remixing these bacterial solutions, they were centrifuged at 3,000 rpm for 10 minutes to separate the supernatant. Using pre-sterilized raw food that had been autoclaved, a 10-fold dilution series (diluted bacterial solution) was prepared from this supernatant in the same manner as above. 100 μL was collected from each 1 mL of the diluted bacterial solution and inoculated onto a culture medium (manufactured by Becton·Dickinson Japan Co., Ltd., AneroColumbia RS Blood Agar Medium (RS medium)), and cultured (anaerobic culture) for 4 days in an anaerobic environment (H2 (10%): N2 (10%): CO2 (80%)) at 35°C. After 4 days of culture, the viable bacteria count in the sample was evaluated based on the number of colonies visually observed on each culture medium. The results are shown in Table 45 below. In Table 45, an action time of 0 minutes indicates the substance immediately after the bacterial solution was prepared (neither the action of the sample nor centrifugation was performed). Additionally, the values in parentheses indicate the ratio of the number of bacteria obtained after the action of each sample to the number of bacteria obtained from the control group.

[0232] ・ Escherichia coli and Vibrio cholerae: For Escherichia coli and Vibrio cholerae, using sterilized raw food, a test bacterial solution with an Mcf (McFarland turbidity standard) of 0.5 was prepared. Then, 30 mg of the above-prepared Samples A - C were each placed in a 1.5 mL microtube, and 1 mL of each test bacterial solution was added to each and mixed. They were left standing at room temperature for the action time shown in Table 45 below (30 minutes or 24 hours) to prepare the test bacterial solution. Additionally, the McFarland turbidity standard (Mcf) is a method for estimating the viable bacteria count concentration of a bacterial solution based on turbidity. Mcf 0.5 corresponds to 1×10 8 CFU / ml and 1×10 7 CFU / ml for Escherichia coli and Vibrio cholerae, respectively. At this time, CFU (colony-forming unit) is the number of colonies formed when inoculated onto a solid culture medium for bacterial growth, and represents the number of proliferable microbial cells contained in the inoculated microorganisms.

[0233] After standing at room temperature for the specified time (30 minutes or 24 hours), the test bacterial solution was mixed again and centrifuged at 3,000 rpm for 10 minutes to separate the supernatant. 10 μL of this supernatant was collected using a large pipette and inoculated onto the medium by the semi-quantitative method using an inoculation loop, and cultured in an atmosphere of 35 °C for the period shown in Table A below (1 day or 4 days) (atmospheric culture). In addition, immediately after preparing the test bacterial solution, 10 μL of the control bacterial solution without the added sample was collected using a large pipette, inoculated onto the medium, and cultured in an atmosphere of 35 °C for 1 day or 4 days (atmospheric culture). In addition, the culture of Escherichia coli was carried out in Pourmedia (registered trademark) Drygalski modified medium (BTB medium) (manufactured by Eiken Chemical Co., Ltd.), and the culture of Vibrio cholerae was carried out in TriptyCase (TM) soy 5% sheep blood agar medium (BA medium) (manufactured by Becton Dickinson Japan Co., Ltd.). In addition, each test was conducted in duplicate.

[0234] After culturing for the specified period (1 day or 4 days), the number of colonies visually confirmed was investigated. The results are shown in Table 46 below. In Table 46 below, "-" indicates that no growth was found.

[0235] [Table 46] Antibacterial evaluation results for spore-forming bacteria

[0236] Antibacterial evaluation results for Escherichia coli

[0237] Antibacterial evaluation results for Vibrio cholerae

[0238] As shown in Table 46 above, among spore-forming bacteria, compared with the control group, the reduction in the number of bacteria remained at 25% - 82% under the action of each sample for 30 minutes, and a reduction in the number of bacteria of 68 - 99.94% was confirmed when acting for 24 hours. This result can be considered that the antibacterial effect is higher than that of the samples of the current products. In contrast, in Escherichia coli (E. coli) and Vibrio cholerae (V. cholerae), no growth of bacteria was found at all under the action of the reagent for 30 minutes. Among them, in the case of Escherichia coli, since Mcf0.5 = 10 8 CFU / mL, it can be considered that the bacterial solution at the start of culture was reduced to 10 6 CFU / mL, but since no growth of bacteria was found at all after culturing, it can be considered to have at least 10 6A control effect of more than CFU / mL (99.9999%). Additionally, in Vibrio cholerae, since Mcf0.5 = 10 7 CFU / mL, it can be considered that the maximum reduction due to centrifugation is down to 10 5 CFU / mL. However, like Escherichia coli, since no growth was found after culturing, it can be considered to have a control effect of more than 10 5 CFU / mL (99.999%). No growth of bacteria was found in either Escherichia coli (E. coli) or Vibrio cholerae (V. cholerae) after 4 days of culturing, so it is considered that all of them died.

[0239] It is speculated that the difference in the results of the above-mentioned spore-forming bacterium (C. difficile) from those of Escherichia coli (E. coli) or Vibrio cholerae (V. cholerae) is mainly affected by the spores possessed by the spore-forming bacterium. Considering that spores are ineffective against disinfectants such as alcohol or benzalkonium chloride and cannot be completely inactivated even by boiling at 100°C (i.e., it is difficult to completely inactivate them), the clinical usefulness of Sample A of the present invention can be expected.

[0240] In addition, in this study, since the reagent was allowed to act in the bacterial solution, the reagent was present floating in the sample. Therefore, the supernatant after centrifugation was used for culturing measurement. Through this centrifugation operation, it was found that the number of Escherichia coli (E. coli) decreased to about 1 / 100, the number of Vibrio cholerae (V. cholerae) decreased to about 1 / 10 - 1 / 100, and the number of spore-forming bacterium (C. difficile) decreased to about 1 / 500. Additionally, by allowing the bacterial solution to stand for 24 hours, it was observed that the number of Escherichia coli (E. coli) decreased to about 1 / 1 - 1 / 10, the number of Vibrio cholerae (V. cholerae) decreased to about 1 / 10 - 1 / 100, and the number of spore-forming bacterium (C. difficile) decreased to about 1 / 10.

[0241] Although the embodiments of the present invention have been described in detail, it is obvious that these are illustrative and exemplary rather than restrictive, and the scope of the present invention should be interpreted by the appended claims.

[0242] The present invention includes the following forms and manners.

[0243] 1. A treatment agent for treating waste liquid, containing slaked lime and pepper.

[0244] 2. The treatment agent according to 1., wherein the pepper is not in the form of a piperine extract.

[0245] 3. The treatment agent according to 1. or 2., containing a water-absorbing polymer.

[0246] 4. The treatment agent according to any one of 1. to 3., wherein the content ratio (mass%) of the slaked lime is 0.1 to 40% by mass, and the content ratio (mass%) of the pepper is 0.05 to 30% by mass.

[0247] 5. The treatment agent according to any one of 1. to 4. contains zinc oxide.

[0248] 6. The treatment agent according to any one of 1. to 5. contains at least one selected from the group consisting of lignin, bentonite, and zeolite.

[0249] 7. The treatment agent according to any one of 1. to 6. further contains humic acid.

[0250] 8. The treatment agent according to any one of 1. to 7., wherein the waste liquid includes excrement, blood, vomit, or body fluids discharged from humans or animals.

[0251] 9. The treatment agent according to any one of 1. to 8., wherein the waste liquid contains at least one of indole and skatole as odor components.

[0252] 10. The treatment agent according to any one of 1. to 9. is used to inhibit or impede the spore germination or proliferation of spore-forming bacteria.

[0253] 11. The treatment agent according to 10., wherein the spore-forming bacteria is Clostridioides difficile.

[0254] 12. A method for inhibiting or impeding the spore germination or proliferation of spore-forming bacteria, comprising the step of bringing the waste liquid into contact with the treatment agent according to any one of 1. to 11.

[0255] The above is the description of the first invention. Next, the description of the second invention will be given.

[0256] <Second Invention> [Invention Name] Waste Liquid Treatment Tool and Downstream Side Waste Liquid Treatment Tool [Technical Field] The present invention relates to a waste liquid treatment tool and a downstream side waste liquid treatment tool.

[0257] [Background Art] Proper treatment of excrement is important for maintaining a hygienic and comfortable environment, but this may become difficult in various situations and places. For example, evacuation shelters where flush toilets cannot be used during emergencies, areas with underdeveloped infrastructure such as mountains or beaches, rooms of nursing care recipients who cannot go to the toilet by themselves, ostomy bags for accommodating the feces of patients who have undergone ostomy surgeries such as colostomy, operating rooms, endoscopy rooms, etc. within hospitals.

[0258] For example, taking an endoscopy room as an example, endoscopes are divided into upper examinations such as examining the stomach through the mouth or nose, and lower examinations such as examining the rectum, large intestine, and small intestine through the anus. During both upper and lower examinations, body fluids are aspirated, and the examination is carried out while washing with water as appropriate. Therefore, waste liquid mixed with excrement, blood, and body fluids is discharged. The waste liquid containing body fluids thus generated is provided for waste treatment.

[0259] In Patent Document 1, as a solution for waste treatment, a disposable synthetic resin collection container was proposed.

[0260] However, even in the case of using a disposable collection container, there is a problem that the waste liquid in the container leaks from the container due to breakage or the like during the stage of transporting the collected container to the treatment facility. This not only poses a hygienic problem but is also sometimes not preferable for the final handler.

[0261] Therefore, in Patent Document 2, in order to provide a treatment container for waste liquid containing body fluids that can easily incinerate the waste liquid containing body fluids stored in the container and is excellent in hygiene and safety, a treatment container for waste liquid containing body fluids is proposed. A waste liquid introduction pipe and an exhaust pipe for discharging the air in the collection container are provided at the upper part of a closed and synthetic resin-made collection container for storing waste liquid containing body fluids. It is characterized in that a coagulant container for accommodating a coagulant composed entirely or mainly of a high molecular water-absorbing polymer is provided at the upper part of the collection container, and an input unit for inputting the coagulant in the coagulant container into the waste liquid stored in the collection container is provided.

[0262] [Prior Art Documents] [Patent Documents] Patent Document 1: Japanese Patent Laid-Open No. 51-48589 Patent Document 2: Japanese Patent Laid-Open No. 02-157083 In Patent Document 2, a container for storing body fluids is connected to a tube, and the body fluids are accommodated in the container by suction. In the container, a treatment agent containing a high molecular water-absorbing body is brought into contact with the body fluids to coagulate the body fluids.

[0263] However, the present inventor has found that according to this method, the solidified substance in the container may be attracted by the downstream tube and block the downstream tube. This situation may occur not only when using an endoscope at the medical site but also when using a device such as a manual pump at the disaster site.

[0264] Therefore, the technical problem of the present invention is to provide a novel technology related to waste liquid treatment. When a treatment agent is pre-configured in a container and a tubular member is connected to the container to collect body fluid into the container, it is possible to prevent the body fluid in contact with the treatment agent from clogging the path of the tubular member connected to the container.

[0265] One aspect of the present invention is a waste liquid treatment tool. The waste liquid treatment tool includes a container, a lid portion, a partition member, and an excrement treatment agent. The container is provided with: an internal space for accommodating body fluid contained in or discharged from a human; and an opening portion through which body fluid can be introduced into the internal space by suction. The lid portion can be attached to the container so as to block the opening portion of the container, and has an inflow portion through which body fluid can flow into the internal space by suction. The partition member is disposed in the internal space and configured to divide the internal space into a first internal space on the proximal side of the opening portion and a second internal space on the distal side that is farther from the opening portion than the first internal space. The excrement treatment agent is disposed in the second internal space of the container and configured to turn body fluid into a solid-like swelling substance by contacting the body fluid. The partition member is configured to allow the body fluid flowing into the internal space from the inflow portion to flow between the first internal space and the second internal space, and to cut off the flow of the swelling substance generated by the contact between the body fluid flowing into the second internal space and the excrement treatment agent to the first internal space.

[0266] In addition, one aspect of the present invention is a downstream waste liquid treatment tool that can be connected to the above waste liquid treatment tool via a tubular member, and includes a second container, a second lid portion, the above excrement treatment agent, and a displacement member. The second container is provided with the above internal space and the above opening portion. The second lid portion can be attached to the second container so as to block the opening portion of the second container, and has the above inflow portion; and a second outflow portion through which gas discharged from the internal space can flow downstream by suction. The excrement treatment agent is disposed in the internal space of the second container and forms a swelling substance by contacting the body fluid. The displacement member cuts off the flow of the body fluid and the swelling substance downstream when the swelling substance generated by the contact between the excrement treatment agent and the body fluid reaches a specified height in the internal space.

[0267] According to the waste liquid treatment tool and the downstream waste liquid treatment tool of one aspect of the present invention, when the treatment agent is pre-configured in the collection container and the tubular member is connected to the container to collect body fluid into the container, it is possible to prevent the body fluid in contact with the treatment agent from clogging the path of the tubular member connected to the container.

[0268] [Description of the Drawings] Figure 2 is a schematic perspective view showing the waste liquid treatment tool and the downstream waste liquid treatment tool of the embodiment.

[0269] Figure 3 isFigure 2 Front view.

[0270] Figure 4 It shows Figure 2 Exploded perspective view of the structure of the waste liquid treatment tool.

[0271] Figure 5 It shows Figure 3 Cross-sectional view along the height direction of the interior of the waste liquid treatment tool.

[0272] Figure 6 It shows the composition of Figure 3 Exploded perspective view of the lid part and the partition member of the waste liquid treatment tool.

[0273] Figure 7 It shows at Figure 6 Exploded perspective view of the lid part and the partition member cut at a different position.

[0274] Figure 8 Exploded perspective view of the structure of the partition member.

[0275] Figure 9 Top view of the partition member.

[0276] Figure 10 It shows Figure 2 Exploded perspective view of the structure of the downstream waste liquid treatment tool shown.

[0277] Figure 11 Cross-sectional view along the height direction of the interior of the downstream waste liquid treatment tool.

[0278] Figure 12 Exploded perspective view showing the lid part, the connecting member, and the mounting member that make up the downstream waste liquid treatment tool, shown in a state where the lid part is cut.

[0279] Figure 13 It shows the lid part, the connecting member, the mounting member, and the displacement member, and shows when gas for suction etc. flows inside the mounting member Figure 10 Enlarged view.

[0280] Figure 14 It shows at Figure 12 The position of the displacement member in Figure 12 A different state enlarged view.

[0281] Figure 15 It shows Figure 3 Exploded perspective view of the waste liquid treatment tool of the modified example.

[0282] Figure 16 It shows Figure 9 Exploded perspective view of the downstream waste liquid treatment tool of the modified example.

[0283] Figure 17 It is a perspective view showing a partition member according to a modified example.

[0284] Figure 18 yes Figure 17 Exploded three-dimensional diagram.

[0285] Figure 19 yes Figure 17 Top view of the .

[0286] Figure 20 It is a perspective view showing a partition member according to a modified example.

[0287] Figure 21 It is shown Figure 13 FIG. 1 is a diagram of a modified example of .

[0288] Figure 22 It is shown Figure 14 FIG. 1 is a diagram of a modified example of .

[0289] Figure 23 It is shown Figure 2 A stereoscopic diagram of a modified example of .

[0290] Figure 24 It is an exploded perspective view showing an interception assembly installed in a waste liquid treatment tool according to a modified example.

[0291] Figure 25 is a diagram showing the interior of the interception assembly.

[0292] [Specific implementation method] Hereinafter, with reference to the attached drawings, the method for implementing the second invention will be described. Figure One The embodiments shown here are exemplified to embody the technical idea of the present invention and do not limit the present invention. In addition, other practicable methods, embodiments and application technologies that can be thought of by those skilled in the art are all included in the scope and gist of the present invention without departing from the gist of the present invention, and are included in the invention described in the claims and their equivalents.

[0293] Furthermore, for the convenience of illustration and understanding, the drawings attached to this specification are sometimes schematically expressed by changing from the actual objects with respect to appropriate scale, aspect ratio, shape, etc., but are ultimately just examples and do not limit the interpretation of the present invention.

[0294] In the following description, ordinal numbers such as “first” and “second” are used for description, but unless otherwise specified, these are used for convenience and do not define a certain order.

[0295] In addition, for ease of explanation, a coordinate system is marked in the drawings. The XY of the orthogonal coordinates is a plane parallel to the plane on which the waste liquid treatment tool 100 or the downstream waste liquid treatment tool 100a is placed, and is referred to as the plane direction XY for convenience. The Z of the orthogonal coordinates is a direction orthogonal to the plane direction XY, and is referred to as the height direction Z for convenience. The r of the cylindrical coordinates refers to the direction from the center of any one of the containers 10, 10a, the lid parts 30, 30a toward the radial direction or the radial direction, and is called the radial direction r. The θ of the cylindrical coordinates refers to the circumferential direction or the angular direction of the container 10, and is referred to as the circumferential direction θ for convenience.

[0296] Hereinafter, with reference to Figures 2 to 14 , the waste liquid treatment tool 100 and the downstream waste liquid treatment tool 100a of the embodiment will be described. Figure 2 is a schematic perspective view showing the waste liquid treatment tool 100 and the downstream waste liquid treatment tool 100a of the embodiment. Figure 3 is Figure 2 front view of. Figure 4 is a perspective exploded view showing the structure of the waste liquid treatment tool 100 of Figure 2 . Figure 5 is a cross-sectional view along the height direction Z showing the inside of the waste liquid treatment tool 100. Figure 6 is a perspective view showing the lid part 30 and the partition member 40 constituting the waste liquid treatment tool 100 of Figure 3 . Figure 7 is a perspective view showing the lid part 30 and the partition member 40 cut at a position different from Figure 6 . Figure 8 is a perspective exploded view showing the structure of the partition member 40. Figure 9 is a top view showing the partition member 40.

[0297] Figure 10 is a perspective exploded view showing the structure of the downstream waste liquid treatment tool 100a. Figure 11 is a cross-sectional view along the height direction Z showing the inside of the downstream waste liquid treatment tool 100a. Figure 12 is a perspective view showing the lid part 30a, the connection member 50 and the mounting member 60 constituting the downstream waste liquid treatment tool 100a. In addition, in Figure 6 , Figure 7 , Figure 12 , for ease of explanation, a part of the lid parts 30, 30a is cut and shown in the drawing. Figure 13 is a magnified view showing the connection member 50, the mounting member 60 and the displacement member 70, and showing the Figure 11 when the gas for suction or the like flows inside the connection member 50. Figure 14 is a magnified view showing a state where the position of the displacement member 70 in Figure 13 is different from Figure 13 .

[0298] The waste liquid treatment tool 100 and the downstream waste liquid treatment tool 100a of this embodiment can be used to treat body fluids discharged from patients using an endoscope in a medical institution such as a hospital, or to treat body fluids discharged from people living in a disaster area in a disaster area. Figure 2 , Figure 3 In the example, two waste liquid treatment tools 100 and one downstream waste liquid treatment tool 100a are prepared, and the respective tools are connected by a tubular member T. Hereinafter, the waste liquid treatment tool 100 and the downstream waste liquid treatment tool 100a will be described.

[0299] <Waste liquid treatment tools> Reference Figure 4 In brief description, the waste liquid treatment tool 100 includes a container 10, an excrement treatment agent 20, a cover 30, a partition member 40, and a connecting member 50. The details will be described below.

[0300] <Container> like Figure 5 As shown, the container 10 is configured to include: an internal space 12 that can accommodate body fluids contained in or discharged from humans; and an opening 11 that can introduce body fluids into the internal space 12. The specific structure of the container 10 is not particularly limited as long as the container does not break when the body fluids are accommodated therein and the internal pressure is kept negative by a pump or the like. A fastening portion (fastening shape) such as an external thread shape that engages with a thread shape provided on a flange portion 32 of a cover portion 30 described below can be provided on the upper portion of the container 10. The container 10 can be made of a material such as a thermoplastic resin such as polyethylene, polypropylene, polycarbonate, ABS (acrylonitrile butadiene styrene), and the thickness, shape, etc. of the container 10 are not particularly limited as long as they are clearly not suitable for accommodating body fluids.

[0301] <Excrement treatment agent> The excrement treatment agent 20 is disposed in the second internal space 14 constituting the internal space 12 of the container 10 and is constituted as a swelling substance w that can solidify the body fluid by contacting the body fluid. Figure 5 The block-shaped structure is shown in the figure, and is configured to form a gap of a degree that can be visually confirmed between adjacent excrement treatment agents 20 when arranged in the internal space 12 of the container 10. With such a structure, when the excrement treatment agent 20 is introduced into the internal space 12 and swells in contact with the body fluid, the excrement treatment agent 20 located at the bottom of the container 10 can be prevented from not being in contact with the body fluid due to the excrement treatment agent 20 located relatively above and swelled earlier.

[0302] The excrement treatment agent 20 contains a water-absorbing polymer. By containing the water-absorbing polymer, moisture and the like in the object to be treated are absorbed, and the treated substance is easily solidified (easily becomes gelatinous). In this specification, the "water-absorbing polymer (water-absorbing resin)" refers to a polymer gelling agent having a water-swellability (CRC) of 5 g / g or more as defined by ERT441.2-02 and a water-soluble component (Ext) of 50% by mass or less as defined by ERT470.2-02.

[0303] In one embodiment of the present invention, as specific examples of the water-absorbing polymer, for example, starch-based water-absorbing polymers such as starch acrylonitrile graft polymer hydrolyzate and starch acrylic acid graft polymer, cellulose-based water-absorbing polymers such as cellulose-acrylonitrile graft polymer and cellulose-styrene sulfonic acid graft copolymer, polysaccharide-based water-absorbing polymers such as pectin, protein-based water-absorbing polymers such as collagen, polyvinyl alcohol-based water-absorbing polymers such as polyvinyl alcohol cross-linked polymer, acrylic acid-based water-absorbing polymers such as sodium polyacrylate cross-linked body, acrylic polymer partial sodium salt cross-linked product, and acrylate-vinyl alcohol copolymer, maleic anhydride-based water-absorbing polymers, vinyl pyrrolidone-based water-absorbing polymers, polyether-based water-absorbing polymers such as polyethylene glycol and diacrylate cross-linked polymer, etc. These water-absorbing polymers can be used alone or in combination of two or more. In addition, these water-absorbing polymers can be synthesized or commercially available products can be used. As examples of commercially available products, for example, AQUAKEEP (registered trademark) SA (manufactured by Sumitomo Seika Chemical Co., Ltd.), AQUALIC (registered trademark) CA (manufactured by Nippon Shokubai Co., Ltd.), SANFRESH (ST-250, ST-100, ST-573), AQUAPEARL (manufactured by sundiapolymer Co., Ltd.), hymosub HS-960 (manufactured by hymo Co., Ltd.), EF polymer (manufactured by EF Polymer Private Limited), etc.

[0304] In one embodiment of the present invention, the water-absorbing polymer can be carboxymethyl cellulose. Carboxymethyl cellulose is a derivative of cellulose, in which carboxymethyl (-CH2-COOH) is bonded to a part of the hydroxyl groups of the pyranose monomers constituting the cellulose backbone. In addition, the carboxymethyl cellulose can be a carboxymethyl cellulose salt. Carboxymethyl cellulose has a high affinity for water and is a thickener that becomes a highly viscous gel-like substance when mixed with water. In the present invention, the thickening of the treatment agent improves the malodor suppression effect and can further maintain the suppression effect.

[0305] According to one embodiment of the present invention, the average particle size of the water-absorbent polymer is 1 to 1200 μm, 50 to 1100 μm, 10 to 1000 μm, 80 to 850 μm, 100 to 600 μm, 150 to 500 μm or 200 to 400 μm.

[0306] According to one embodiment of the present invention, the treatment agent can be granulated using water, PVA, cellulose, water-soluble cellulose, water-soluble carboxymethyl cellulose, sodium alginate and other adhesives. That is, according to one embodiment of the present invention, the treatment agent is a block treatment agent. In addition, the treatment agent of one embodiment of the present invention can be formed into a granular treatment agent or a block treatment agent using the technology of Japanese Patent Publication No. 2013-6137 or Japanese Patent Publication No. 2011 / 162244. According to one embodiment of the present invention, the treatment agent contains a lubricant. When making a block treatment agent, the lubricant is particularly used to make the feeding to the mortar of the tablet press smooth. Therefore, as the type of lubricant, it is possible to appropriately select previously known types or use them in combination. For example, esters, silicones, stearates, calcium stearate, potassium stearate, calcium, zinc, etc. are used.

[0307] According to one embodiment of the present invention, the average diameter of the treatment agent is 3 to 100 mm or 5 to 50 mm. In this specification, "average diameter" refers to the average value obtained by arbitrarily selecting a statistically reliable number of particles (or 10, 100, 200, 300 or 1000) and measuring the longest particle size for each particle with a vernier caliper, and adding and averaging them, unless otherwise specified. In addition, the excrement treatment agent 20 is not limited to a block or granular form, and can also be configured as a powder. In this case, according to one embodiment, the average particle size of the treatment agent is 10 μm or more, 30 μm or more, 50 μm or more, 100 μm or more, 300 μm or more, 500 μm or more, 700 or more, 1 mm or more, or 2 mm or more. According to one embodiment, the average particle size of the treatment agent is 3 mm or less, 2 mm or less, 1000 μm or less, 700 μm or less, 500 μm or less, 300 μm or less, 100 μm or less, 50 μm or less, or 30 μm or less. According to one embodiment, it is 10 μm to 30 μm, 30 μm to 50 μm, 50 μm to 100 μm, 100 μm to 300 μm, 300 μm to 500 μm, 500 μm to 700 to 1000 μm, 1 mm to 2 mm, or 2 mm to 3 mm.

[0308] <Cover> The lid portion 30 is configured to be attachable to the container 10 to block the opening 11 of the container 10. With this configuration, the user can enclose the inner space 12 of the container 10 with the excrement treatment agent 20 and the partition member 40 installed in the inner space 12 of the container 10.

[0309] As Figure 5 shown, etc., the lid portion 30 has a covering portion 31, a flange portion 32, a connecting portion 33 (equivalent to the inflow portion), a connecting portion 34 (equivalent to the outflow portion), and an engaging recess 35. The covering portion 31 is configured to cover the opening 11 of the container 10 when the lid portion 30 is attached to the container 10. The covering portion 31 is formed in a shape having a concave step provided substantially at the center, except for the shapes of the connecting portions 33 and 34. However, as long as it can cover the opening 11 of the container 10 when attached to the container 10, the specific shape is not limited to the above shape and may also be a simple plane.

[0310] The flange portion 32 is formed to descend in the height direction Z from the outer peripheral edge portion of the covering portion 31. The flange portion 32 is configured to cover the upper outer side surface of the container 10 when attached to the container 10. The flange portion 32 is configured to be provided with an internal thread or the like that can be screwed with a threaded portion provided on the outer side surface of the container 10. The specific shape of the fastening portion (fastening shape) such as the internal thread provided on the flange portion 32 is not particularly limited as long as it can generate a suction force in the inner space 12 when the lid portion 30 is attached to the container 10, or the generated suction force will not be extremely reduced due to accidental gas leakage or the like.

[0311] The connecting portions 33 and 34 are provided to penetrate through the lid portion 30 inside and outside, and are configured to be attachable to the connecting member 50. The connecting member 50 can connect to a tubular member T that allows body fluid to flow through the inner space 12 of the container 10 by suction. Through the connection between the connecting member 50 and the tubular member T, the connecting portion 33 functions as an inflow portion through which body fluid or the like can flow in the inner space 12 by suction, and the connecting portion 34 functions as an outflow portion through which at least one of the gas and body fluid discharged from the inner space 12 can flow out to the downstream side by suction.

[0312] The engaging recess 35 is configured to be engageable with the engaging convex portion p3 so that the partition member 40 can be positioned in the inner space 12 when the lid portion 30 is attached to the container 10. The engaging recess 35 is configured to be provided on the inner space 12 side when the lid portion 30 is attached to the container 10. In the present embodiment, the engaging recess 35 is configured to have two cylindrical recesses that can be engaged with the engaging convex portion p3 of the partition member 40 (see Figure 6 ). However, as long as the partition member can be positioned relative to the lid portion, the engaging shape or the number of shapes is not limited to the above.

[0313] <Partition member> AsFigure 5 As shown in etc., the partition member 40 is disposed in the internal space 12 and configured to divide the internal space 12 into a first internal space 13 on the proximal side of the opening 11 and a second internal space 14 on the distal side farther from the opening 11 than the first internal space 13. The partition member 40 can allow the body fluid flowing into the internal space 12 from the connecting portion 33 to flow between the first internal space 13 and the second internal space 14. In addition, the partition member 40 is configured to cut off the flow of the swelling substance w (refer to the double-dashed line in Figure 5 ) generated by contacting the body fluid flowing into the second internal space 14 with the excrement treatment agent 20 from flowing into the first internal space 13.

[0314] The partition member 40 is disposed in the internal space 12 at a position closer to the opening 11 than the excrement treatment agent 20. As Figure 8 shown, the partition member 40 has a first member 41 and a second member 42. The first member 41 and the second member 42 are configured to have a small (thin) thickness dimension in the height direction Z and are stacked in the thickness direction to be integrally formed.

[0315] The first member 41 allows the body fluid to flow between the first internal space 13 and the second internal space 14.

[0316] In the present embodiment, the second member 42 is configured in pairs so as to sandwich the first member 41. As Figure 8 shown in etc., the second member 42 has a covering portion p1, a hole portion p2, an engaging convex portion p3, a first wall portion p4, and a second wall portion p5.

[0317] The covering portion p1 is configured to be a portion that locally covers without exposing one side of the first member 41. The hole portion p2 is configured to be a portion where one side of the first member 41 is exposed. In the present embodiment, it is configured that the covering portion p1 is provided on the outer side in the radial direction r of the partition member 40, and the hole portion p2 is provided on the inner side in the radial direction r of the partition member 40. In addition, the specific shape of the hole portion p2 is not limited to the shape shown in the figure, as long as it can allow the body fluid etc. to flow from the first internal space 13 to the second internal space 14 and hinder the movement of the swelling substance w from the second internal space 14 to the first internal space 13.

[0318] The engaging convex portion p3 is configured to be engageable with the engaging concave portion 35 of the lid portion 30 as described above. In the present embodiment, two engaging convex portions p3 are provided in the same way as the engaging concave portion 35 of the lid portion 30, but the specific number may not be two as described above, and the shape may also be Figure 8 other shapes than etc. In addition, in Figure 6 the lid portion 30 is provided with the engaging concave portion 35, and the partition member 40 is provided with the engaging convex portion p3, but as long as the two can be engaged, the convex portion may be provided on the lid portion and the concave portion may be provided on the partition member, contrary to the above.

[0319] The first wall portion p4 is configured to be disposed in the first internal space 13 in a state where the partition member 40 is disposed in the internal space 12, and is disposed adjacent to the connecting portion 34 between the connecting portion 33 and the connecting portion 34. Thereby, it is possible to prevent or suppress body fluids flowing into the internal space 12 from the connecting portion 33 from flowing into the second internal space 14 as shown by the arrow r2 in Figure 7 and flow downstream through the flow path of the connecting member 50 mounted on the connecting portion 34 as shown by the arrow r1 in Figure 7 .

[0320] The second wall portion p5 is provided at or near the outer peripheral edge portion of the covering portion p1. The second wall portion p5 is configured to be disposed adjacent to the connecting portion 33 in the first internal space 13 in a state where the partition member 40 is disposed in the internal space 12. Although there may be a gap between the partition member 40 and the container 10 when the partition member 40 is disposed in the container 10, by providing the second wall portion p5, it is possible to promote the flow of body fluids flowing in from the connecting portion 33 to a place other than the boundary between the container 10 and the partition member 40. That is, in the present specification, the partition member 40 allows a gap to be generated between the inner wall surface of the container 10 and the outer peripheral edge portion of the partition member 40.

[0321] The second members 42 are disposed in pairs on the outside so as to sandwich the first member 41. However, if the partition member 40 has the first member, the first member may not be sandwiched by the second members. In addition, the second members 42 use the same components on the upper side and the lower side in a state where the first member 41 is disposed in the container 10. However, if the first wall portion p4 and the second wall portion p5 are provided on the second member on the upper side in the set state, the first wall portion and the second wall portion may not be provided on the second member on the lower side. The second member 42 is configured to have a higher rigidity than the first member 41.

[0322] Regarding the material of the partition member 40, the first member 41 can contain cotton, non-woven fabric, woven fabric, cotton, paper, etc. The second member 42 can contain materials such as polyethylene or polypropylene. The pore size of the first member 41 such as non-woven fabric can be smaller than the size of the swollen water-absorbing resin. In addition, in order to promote the flow of body fluids flowing into the first internal space 13 into the second internal space 14, the partition member 40 can perform a hydrophilic surface treatment on the surface on the first internal space 13 side. The surface treatment of the partition member 40 on the second internal space 14 side may or may not be provided, but it is preferably not provided.

[0323] Here, an example shows the dimensions of relevant parts such as the partition member 40 and the container 10 that prevent the swollen substance w from flowing into the first internal space 13 when the swollen substance w is generated in the second internal space 14. The dimension d1 in the radial direction r of the opening portion 11 of the container 10 (refer to Figure 5) can be configured to be about 135 mm. The size of the hole portion p2 of the first member 41 is preferably smaller than the swelling substance w so that the swelling substance w generated by contacting the excrement treatment agent 20 in the second internal space 14 does not flow into the first internal space 13. Regarding the hole portion p2 of the partition member 40, the dimensions of the respective portions of the plurality of hole shapes that constitute the hole portion p2 in the surface direction XY are set to 1 to 40% of the area when covering portion p1 is viewed from the height direction Z assuming that there is no hole portion p2. The thickness of the first member 41 and the thickness of the second member 42 of the partition member 40 (refer to Figure 8 ) can be configured to be approximately 1.4 mm. If the excrement treatment agent 20 is considered approximately cylindrical, the dimension d2 of the radial direction r can be configured to be about 13 mm, and the dimension d3 in the height direction Z (refer to Figure 5 ) is 5 to 6 mm.

[0324] <Connecting member> The connecting member 50 is used to connect adjacent waste liquid treatment tools 100 or downstream waste liquid treatment tools 100a to each other via the tubular member T. The connecting member 50 is installed at the connecting portions 33 and 34 of the lid portion 30 through which body fluid flows in and out of the internal space 12. As Figure 5 shown, the connecting member 50 has an outer portion 51 and an inner portion 52. The connecting member 50 is formed in a hollow cylindrical shape so that in the installed state of the lid portion 30, body fluid from the upstream side can flow into the internal space 12 at the connecting portion 33, and body fluid located in the internal space 12 of the container 10 can flow to the downstream side at the connecting portion 34.

[0325] The outer portion 51 corresponds to the portion disposed outside the internal space 12 in the state of being installed on the lid portion 30. In the present embodiment, the outer portion 51 is configured to be bent into a substantially L shape and the tubular member T is connected to the front end portion. Here, the shape of the outer portion is not limited to the L shape as long as it can connect the tubular member T, and it may also be a linear shape or the like.

[0326] The inner portion 52 corresponds to the portion located in the internal space 12 in the state of being installed on the lid portion 30. The outer portion 51 and the inner portion 52 are provided with flow paths through which body fluid can flow into and out of the internal space 12. The inner portion 52 is configured to be provided with a sealing member such as rubber or an elastomer at the connecting portions 33 and 34 so that body fluid does not leak from portions other than the flow paths. In addition, the connecting member 50 can abut against the displacement member 70 of the downstream waste liquid treatment tool 100a described below at the lower end of the inner portion 52, and the portion that abuts against the displacement member 70 and becomes a part of the flow path is referred to as the opening end portion 53 (refer to Figure 13 ). Details will be described later.

[0327] The tubular member T connected to the connecting portions 33 and 34 of the lid portion 30 can be made of a known flexible material such as plastic, so that it can be connected to the connecting portions 33 and 34 in various postures.

[0328] <Downstream waste liquid treatment tool> The downstream waste liquid treatment tool 100a is configured to be connected to the waste liquid treatment tool 100 via the tubular member T and is disposed at a position downstream of the waste liquid treatment tool 100. As Figure 10 shown, the downstream waste liquid treatment tool 100a has a container 10a (equivalent to the second container), an excrement treatment agent 20, a lid portion 30a (equivalent to the second lid portion), a connecting member 50, a mounting member 60, and a displacement member 70. The container 10a is the same as the container 10 of the waste liquid treatment tool 100, and the excrement treatment agent 20 and the connecting member 50 are the same as the respective structural components of the waste liquid treatment tool 100, so detailed description thereof is omitted.

[0329] <Lid portion> The lid portion 30a is configured to be mounted on the container 10a so as to block the opening 11 of the container 10a. As Figure 11 shown, the lid portion 30a has a covering portion 31, a flange portion 32, a connecting portion 33 (equivalent to the inflow portion), and a connecting portion 34a (equivalent to the second outflow portion). The lid portion 30a is different from the lid portion 30 and does not have the engaging recess 35. On the other hand, like the lid portion 30, it has a covering portion 31, a flange portion 32, and a connecting portion 33. In addition, the connecting portion 34a is configured in the same manner as the connecting portion 34 to allow the gas discharged from the internal space 12 by suction to flow downstream while not allowing the swelling substance w to flow through. On the other hand, different from the connecting portion 34, it is configured not to allow the body fluid to flow downstream by suction. However, the specific shape of the connecting portion 34a can be configured to be the same as that of the connecting portion 34. Therefore, the description of the covering portion 31, the flange portion 32, and the connecting portions 33 and 34a is omitted.

[0330] <Mounting member> The mounting member 60 can be mounted on the lid portion 30a and is configured to allow the flow of gas and the like sucked by a pump, and can place the displacement member 70 when the displacement member 70 described below does not cut off the flow of the swelling substance w. As Figure 12 , Figure 13 etc. shown, the mounting member 60 has a fixing portion 61, a hanging portion 62, an abutting portion 63, a circulation hole 64, and an insertion through hole 65.

[0331] The fixing portion 61 has a flange provided with a hole that can be engaged with a convex shape (not shown) provided on the lid portion 30a for mounting the mounting member 60 by fitting or the like. The fixing portion 61 is configured to have a flange that extends horizontally in the XY plane direction from the end of the hanging portion 62.

[0332] The hanging portion 62 is configured to extend downward from the inner end of the flange of the fixing portion 61. In the present embodiment, the hanging portion 62 extends linearly in parallel with the height direction Z, but may be inclined with respect to the height direction Z or curved as long as the following circulation hole 64 can be provided.

[0333] The abutting portion 63 holds the displacement member 70 near the connecting portion 34a of the internal space 12 when the displacement member 70 does not cut off the flow path of the connecting member 50 to which the connecting portion 34a is attached. As Figure 13 shown, the abutting portion 63 is configured to extend from the lower end of the hanging portion 62 toward the inside of the hanging portion 62 in the plane direction XY. The abutting portion 63 is formed to be substantially flat so as to be able to abut against the fall-preventing portion 72 of the displacement member 70. When the displacement member 70 does not at least partially block the opening end 53 of the connecting member 50, the displacement member 70 can be placed on the abutting portion 63.

[0334] As Figure 12 shown, the circulation hole 64 is a cut provided in the hanging portion 62, and thus is configured to allow gas or the like sucked by a pump or the like to flow between the internal space 12 and the outside through the flow path of the connecting member 50. A plurality of circulation holes 64 can be provided on the side surface of the hanging portion 62, and in particular, as Figure 12 shown, they are provided in the circumferential direction θ. It is configured such that by inserting the insertion portion 73 of the following displacement member 70 into the insertion hole 65, the displacement member 70 can move in the height direction Z with respect to the mounting member 60. The insertion hole 65 is configured to be provided substantially at the center of the abutting portion 63.

[0335] <Displacement member> The displacement member 70 is configured to abut against or separate from the opening end 53 of the connecting member 50 provided at the connecting portion 34a. As Figure 13 shown, the displacement member 70 has a blocking portion 71, a fall-preventing portion 72, an insertion portion 73, a reverse end portion 74, and a floating portion 75.

[0336] The blocking portion 71 is configured to at least partially block the flow path of the connecting member 50 attached to the connecting portion 34a. The blocking portion 71 is configured to include a curved surface provided at the top of the displacement member 70. By bringing this curved surface into contact with the opening end 53 of the inner portion 52 of the connecting member 50, it is possible to prevent body fluids and swelling substances w that may exist in the internal space 12 from flowing into the flow path of the connecting member 50 attached to the connecting portion 34a.

[0337] In the present embodiment, the anti-falling part 72 is provided on the opposite side of the curved surface of the blocking part 71 and is configured to be able to abut against the abutting part 63 of the mounting member 60. The anti-falling part 72 is configured such that by abutting against the abutting part 63, the mounting member 60 can hold the displacement member 70 at a position near the connecting part 34a in the internal space 12. The anti-falling part 72 can be configured to include a flat surface or the like provided on the opposite side of the curved surface of the blocking part 71.

[0338] The insertion part 73 can be inserted through the insertion hole 65 of the mounting member 60 and is configured to include a cylindrical shape in the present embodiment. Thereby, the displacement member 70 can be moved to a position where the blocking part 71 of the displacement member 70 blocks the flow path of the connecting member 50, or to a position where the anti-falling part 72 abuts against the abutting part 63. In addition, the specific shape of the insertion part 73 is not limited to the above-mentioned cylindrical shape, as long as the blocking part 71 can be moved to a position where it blocks the flow path of the connecting member 50 or to a position where it does not block the flow path.

[0339] The opposite-side end part 74 is configured to be provided on the opposite side of the blocking part 71 with respect to the insertion part 73. The opposite-side end part 74 is formed to protrude outward from the center of the insertion part 73 in the surface direction XY according to the shape of the insertion part 73, so that it can function as a stopper to prevent the displacement member 70 from moving excessively upward with respect to the mounting member 60.

[0340] The floating part 75 is provided at the lower end in the gravitational direction in the set state and is configured to float the displacement member 70 on the liquid surface in a state of contacting the liquid surface of the body fluid in the internal space 12. Here, sometimes there is not only body fluid but also a swelling substance w on the liquid surface formed by the fluid flowing into the internal space 12, and hereinafter, it is only described as "the liquid surface of the body fluid". The floating part 75 can be joined to the opposite-side end part 74 by pasting or welding or the like. The floating part 75 can be formed of a lighter member different from the member provided with the blocking part 71, the anti-falling part 72, the insertion part 73, and the opposite-side end part 74. The floating part 75 can be configured to contain foamed plastics such as polyurethane or styrofoam. In addition, in Figure 13 etc., the opposite-side end part 74 is formed to protrude outward in the radial direction r so that the displacement member 70 does not completely come out of the insertion hole 65 of the mounting member 60 upward. However, as long as it is a shape in which the floating part 75 does not pass through the insertion hole 65 when moving upward, the opposite-side end part 74 may not be a shape that protrudes outward in the radial direction r in a manner that cannot pass through the insertion hole 65.

[0341] In addition, a flow-through mechanism that allows the suction of gas while suppressing the suction of liquid during suction can be provided on the displacement member 70. If an example of the flow-through mechanism is given, insertion holes h1 of about several millimeters in size can be provided on the member provided with the blocking part 71, the anti-falling part 72, the insertion part 73, and the opposite-side end part 74 (refer to Figure 13, 14 ), numerous extremely minute holes are provided on the floating portion 75 by means of foamed plastics or the like.

[0342] As Figure 13 shown, when the anti-falling portion 72 abuts against the abutting portion 63 of the mounting member 60, the displacement member 70 is in a state where it does not block the opening end 53 of the inner portion 52 of the connecting member 50. Thus, as Figure 12 indicated by the arrow in, gas or the like existing in the internal space 12 of the container 10a can flow through the circulation hole 64 from the opening end 53 of the connecting member 50 to the flow path of the connecting member 50. On the other hand, if the liquid level of the body fluid existing in the internal space 12 further rises from the state of contacting the floating portion 75, the anti-falling portion 72 separates from the abutting portion 63, the displacement member 70 moves upward, and the blocking portion 71 abuts against the opening end 53 of the inner portion 52 of the connecting member 50. As a result, the opening end 53 is in a state of being blocked by the blocking portion 71. As a result, liquids such as body fluid or swelling substance w existing in the internal space 12 become unable to flow through the opening end 53 of the connecting member 50. On the other hand, even in the state where the blocking portion 71 abuts against the opening end 53 of the inner portion 52, the gas existing in the internal space 12 can flow downstream through the minute holes of the floating portion 75 and the insertion through-hole h1.

[0343] As described above, in the present embodiment, the waste liquid treatment tool 100 includes a container 10, an excrement treatment agent 20, a lid portion 30, and a partition member 40. The container 10 is provided with an internal space 12 that can accommodate body fluid contained in or discharged from a human, and an opening 11 through which body fluid can be introduced into the internal space 12 by suction. The lid portion 30 can be installed so as to block the opening 11 of the container 10, and has a connecting portion 33 through which body fluid can flow into the internal space by suction. The partition member 40 is disposed in the internal space 12 and is configured to divide the internal space 12 into a first internal space 13 on the proximal side of the opening 11 and a second internal space 14 on the distal side that is farther from the opening 11 than the first internal space 13. The excrement treatment agent 20 is disposed in the second internal space 14 of the container 10 and is configured to turn the body fluid into a solid-like swelling substance w by contacting the body fluid. The partition member 40 can allow the body fluid flowing into the internal space 12 from the connecting portion 33 to flow between the first internal space 13 and the second internal space 14. In addition, the partition member 40 is configured to cut off the flow of the swelling substance w generated by contacting the body fluid flowing into the second internal space 14 with the excrement treatment agent 20 to the first internal space 13.

[0344] With this configuration, it is possible to prevent substances generated by the contact between body fluids and the excrement treatment agent 20 from clogging the outlet-side flow path of the lid portion 30, that is, the connection portion 34. In addition, at a medical site or the like, when a test body is collected from a patient's body, even if the collected test body is erroneously collected into the inner space 12 of the container 10, the swelling substance w can be disposed in an inner space (second inner space 14) different from the first inner space 13 where the test body is located by the partition member 40. Thereby, it is possible to prevent the swelling substance w and the test body from being mixed, and it is relatively easy to take out the test body from the inner space 12 of the container 10.

[0345] In addition, the partition member 40 includes a first member 41 that allows body fluids to flow between the second inner space 14 and the first inner space 13, and a second member 42 having a higher rigidity than the first member 41. With this configuration, when the swelling substance w is generated in the second inner space 14, it is difficult for the swelling substance w to deform the partition member 40. Thereby, it is possible to prevent the flow path of the connection portion 34 of the lid portion 30 from being clogged by the swelling substance w when the excrement treatment agent 20 swells by contact with body fluids.

[0346] In addition, the lid portion 30 has a connection portion 34 as an outflow portion that allows at least one of the gas and body fluids discharged from the inner space 12 to flow downstream through suction. The second member 42 has a first wall portion p4 that is disposed in the first inner space 13 in a state where the partition member 40 is disposed in the inner space 12 and is disposed adjacent to the connection portion 34 between the connection portion 33 and the connection portion 34. With this configuration, it is possible to prevent or suppress the body fluid flowing in from the connection portion 33 from flowing downstream from the connection portion 34 without passing through the hole portion p2 and moving from the first inner space 13 to the second inner space 14.

[0347] In addition, the second member 42 has a covering portion p1 and a second wall portion p5. The covering portion p1 partially covers one side of the first member 41. The second wall portion p5 is disposed at or near the outer peripheral edge portion of the covering portion p1 and is disposed adjacent to the connection portion 33 in the first inner space 13 in a state where the partition member 40 is disposed in the inner space 12. Thereby, it is possible to suppress the body fluid flowing into the inner space 12 from the connection portion 33 from reacting only with the excrement treatment agent 20 disposed below the connection portion 33 in the second inner space 14, and to promote the body fluid to also flow to the excrement treatment agent 20 disposed below the connection portion 34.

[0348] In addition, the second members 42 are paired so as to sandwich the first member 41. With this configuration, in the second inner space 14, when the body fluid contacts the excrement treatment agent 20 and the swelling substance w is generated, it is difficult to deform the partition member 40 in the inner space 12. Thereby, it is possible to prevent the flow path of the connection portion 34 of the lid portion 30 from being clogged by the swelling substance w when the excrement treatment agent 20 swells by contact with body fluids.

[0349] In addition, in the present embodiment, the partition member 40 is configured to be provided with an engaging convex portion p3, and the lid portion 30 is provided with an engaging concave portion 35, so that in a state where the lid portion 30 is attached to the container 10, the partition member 40 is positioned in the internal space 12. By configuring in this way, it is possible to make it difficult for the partition member 40 to shift from the desired position in the internal space 12, thereby preventing the swelling material w from clogging the flow path of the connecting portion 34 of the lid portion 30 when the excrement treatment agent 20 swells by contacting body fluid.

[0350] In addition, the downstream waste liquid treatment tool 100a includes a container 10a, a lid portion 30a that can be attached to the container 10a so as to block the opening 11 of the container 10a, an excrement treatment agent 20, and a displacement member 70. The container 10a is provided with an internal space 12 and an opening 11. The lid portion 30a can be attached to the container 10a so as to block the opening 11 of the container 10a, and has a connecting portion 33 and a connecting portion 34a through which the gas discharged from the internal space 12 can flow downstream by suction. The excrement treatment agent 20 is disposed in the internal space 12 of the container 10a and is configured to turn body fluid into a swelling material w by contacting the body fluid. The displacement member 70 is configured to cut off the flow of the body fluid and the swelling material w downstream when the swelling material w generated by the contact between the excrement treatment agent 20 and the body fluid reaches a specified height in the internal space 12.

[0351] By configuring in this way, it is possible to recover the swelling material w in the internal space 12 of the downstream waste liquid treatment tool 100a and prevent the body fluid and the swelling material w from flowing downstream.

[0352] In addition, the downstream waste liquid treatment tool 100a includes a mounting member 60. The mounting member 60 can be attached to the lid portion 30a and is configured to have an abutting portion 63 that holds the displacement member 70 near the connecting portion 34a in the internal space 12 when the displacement member 70 does not cut off the flow of the body fluid and the swelling material w. Thus, in the internal space 12 of the container 10a, the displacement member 70 can be made to standby when the liquid level of the body fluid rises, so that the flow of the body fluid and the swelling material w to the flow path of the connecting member 50 attached to the connecting portion 34a can be blocked by the displacement member 70.

[0353] In addition, the displacement member 70 has a blocking portion 71 and a fall prevention portion 72. The blocking portion 71 is configured to at least partially block the flow path of the connection member 50 mounted on the connection portion 34a. The fall prevention portion 72 can abut against the abutting portion 63 of the mounting member 60, and the displacement member 70 is held at a position near the connection portion 34a in the internal space 12 by the abutment. Thus, when body fluid flows into the internal space 12 of the container 10a and the body fluid does not block the flow path of the connection member 50 mounted on the connection portion 34a, the displacement member 70 can be standby at a position where the flow of the body fluid and the swelling substance w can be blocked.

[0354] In addition, the displacement member 70 is configured to have a floating portion 75 provided at the lower end in the direction of gravity, and the displacement member 70 can be floated on the liquid surface of the body fluid in a state of being in contact with the liquid surface of the body fluid in the internal space 12. Thus, it is easy to move the displacement member 70 upward according to the rise of the body fluid liquid surface, and the displacement member 70 can be moved to a position covering the flow path of the connection member 50 so that the body fluid and the swelling substance w do not flow into the flow path of the connection member 50 mounted on the connection portion 34a.

[0355] In addition, a flow mechanism that allows suction of gas while suppressing suction of liquid during suction can be provided on the displacement member 70. With this configuration, even when the blocking portion 71 blocks the opening end portion 53 of the inner side portion 52 of the connection member 50, gas or the like can be suctioned by a pump or the like disposed on the downstream side.

[0356] In addition, the present invention is not limited to the above-described embodiments, and various changes can be made in the claims. In Figure 2 etc., it is described that two waste liquid treatment tools 100 are prepared and one downstream waste liquid treatment tool 100a is prepared. However, as long as it is possible to treat body fluids and the like required at a medical site or a disaster site, etc., the specific number of the waste liquid treatment tool and the downstream waste liquid treatment tool is not limited to Figure 2 etc. In addition, if it is possible to treat the required body fluids and the like, the waste liquid treatment tool 100 can be prepared without preparing the downstream waste liquid treatment tool 100a.

[0357] Figure 15 is Figure 4 an exploded perspective view of a waste liquid treatment tool 100b which is a modified example of Figure 16 is Figure 10Exploded perspective view of the downstream waste liquid treatment tool 100c of the modified example. In the above description, it was explained that the internal space 12 of the container 10 of the waste liquid treatment tool 100 or the downstream waste liquid treatment tool 100a houses the excrement treatment agent 20, etc. When the body fluid contacts the excrement treatment agent 20 and a swelling substance w is generated, the swelling substance w existing in the internal space 12 can be discarded together with the container 10. However, as long as the swelling substance w, etc. can be disposed of, the container 10 does not necessarily have to be discarded together with the swelling substance w every time the swelling substance w is generated. That is, on the basis of disposing a disposable bag 80 such as a plastic bag in the internal space 12 of the container 10 of the waste liquid treatment tool 100b or the downstream waste liquid treatment tool 100c, the excrement treatment agent 20 is provided inside the disposable bag 80 (refer to Figure 15 , Figure 16 ).

[0358] The disposable bag 80 can be the above-mentioned plastic bag, drawstring bag, or zippered bag. By configuring it in this way, when the swelling substance w is generated, the disposable bag 80 is discarded together with the swelling substance w, and at least one of the containers 10, 10a of the waste liquid treatment tool and the downstream waste liquid treatment tool can be reused.

[0359] In addition, in the above description, it was described that the partition member 40 includes the first wall portion p4 and the second wall portion p5. However, as long as the body fluid flowing into the internal space 12 from the connection portion 33 can flow to the second internal space 14, the partition member 40 can also be configured not to include the first wall portion p4 and the second wall portion p5 or to include only any one of the first wall portion p4 and the second wall portion p5.

[0360] In addition, it was described that the displacement member 70 includes the floating portion 75, but as long as it can contact the liquid level of the body fluid in the internal space 12 of the container 10a and move the displacement member upward according to the rise of the liquid level, the displacement member may not have the floating portion 75.

[0361] Figure 17 Is a perspective view showing the structure of the partition member 40d of the modified example, Figure 18 Is Figure 17 The exploded perspective view of, Figure 19 Is Figure 17 The top view of, Figure 20 Is a perspective view showing the partition member 40e of the modified example.

[0362] In Figure 8The partition member 40 among others has a first member 41 and a second member 42, and the first member 41 is configured to be disposed between two second members 42. However, as long as the body fluid flowing into the internal space 12 from the connection portion 33 can flow between the first internal space 13 and the second internal space 14, and the swelling substance w generated in the second internal space 14 does not flow into the first internal space 13, the specific form of the partition member is not limited to the above structure.

[0363] In addition to the above structure, the partition member 40d may also be such that Figure 17 as shown in etc., a first member 41d provided with a plurality of holes is disposed on the second member 42d. The first member 41d is provided with countless holes in a substantially circular shape.

[0364] As Figure 18 shown, the second member 42d has a covering portion p1d, a hole portion p2d, and an engaging convex portion p3d. The covering portion p1d is formed in an outer peripheral shape substantially the same as the horizontal cross-sectional shape at the installation position of the container 10. The hole portion p2d can be provided with a hole portion on the entrance side and a hole portion on the exit side (see Figure 18 ) where the body fluid can flow from the first internal space 13 to the second internal space 14 in at least a part of the first member 41d in a state where the first member 41d is provided. The engaging convex portion p3d is configured in the same manner as the engaging convex portion p3 of the partition member 40. The portion corresponding to the first wall portion p4 of the partition member 40 can be provided as a wall member 43d on the first member 41d. The wall member 43d is disposed close to the connection portion 34 on the path between the connection portion 33 and the connection portion 34 of the cover portion 30 where the body fluid flows in the internal space 12. The wall member 43d prevents or inhibits the body fluid from flowing downstream from the first internal space 13 without passing through the second internal space 14 in the same manner as the first wall portion p4 of the partition member 40.

[0365] In addition, although the first member 41d, the second member 42d, and the wall member 43d of the partition member 40d are respectively constituted by different components, it may also be such that Figure 20The above-described separating member 40e is formed of a single part for these members. In this case, the numerous holes of the first member 41d can be used as the holes p2e, instead of the case where the holes p2d of the separating member 40d are not provided. The covering portion p1e is a flat portion where no holes p2e are provided outside the holes p2e, and the engaging convex portion p3e and the first wall portion p4e can be formed in the same manner as the engaging convex portion p3 and the first wall portion p4d of the separating member 40d, respectively. The second wall portions p5e, p6e, p7e include a second wall portion p5e having a larger size and second wall portions p6e, p7e that are smaller in size than the second wall portion p5e, are spaced apart in the circumferential direction, and are arranged in pairs. However, as long as body fluid can flow from the holes p2e to the second internal space 14 in the separating member 40, the second wall portions p6e, p7e may not be provided.

[0366] Figure 21 is a view showing Figure 13 a modified example of Figure 22 is a view showing Figure 14 a modified example of Figure 13 , Figure 14 In, the displacement member 70 of the downstream-side waste liquid treatment tool 100a includes a blocking portion 71, a fall-preventing portion 72, an insertion portion 73, a counter-side end portion 74, and a floating portion 75. The blocking portion 71 of the displacement member 70 is provided at the upper front end portion of the displacement member 70, but is not limited thereto, and the blocking portion 71d can also be provided on the front end surface of the floating portion 75d. The fall-preventing portion 72 of the displacement member 70 is provided on the side opposite to the blocking portion 71, but the fall-preventing portion 72d of the displacement member 70d can be an end surface having a stepped shape made of plastic or the like. In addition, the insertion portion 73d can be a longitudinal wall having a stepped cylindrical shape. In addition, the counter-side end portion 74d can be a cylindrical end portion that contacts the floating portion 75. The floating portion 75d is integrally joined to the cylindrical shape having the fall-preventing portion 72d or the counter-side end portion 74d and can be formed of a foaming material such as polyurethane.

[0367] Figure 23 is a perspective view showing Figure 2 a modified example of Figure 24 is an exploded perspective view showing the interception assembly 80d, Figure 25 is a view showing the inside of the interception assembly 80d. The waste liquid treatment tool 100 and the waste liquid treatment tool 100 can be connected by a connecting member 50, but the interception assembly 80d (corresponding to the interception portion) can also be installed in place of the connecting member 50 on the connecting portion 33 of the waste liquid treatment tool 100 located at the most upstream in the waste liquid treatment tool 100 shown in Figure 2 (see Figure 23 ).

[0368] As shown in Figure 24As shown, the interception component 80d has a cover portion 81, a container 85, and a partitioning portion 91.

[0369] The cover portion 81 has a mounting portion 82, an upper portion 83, and a side portion 84. The upper portion 83 is configured to block the opening portion 88 of the container 85. The side portion 84 is provided connected to the outer periphery of the upper portion 83 and is configured to be connectable to the container 85. The inner side of the side portion 84 can be fitted with the container 85 or can be connected to the container 85 by being formed in a threaded shape or a groove shape. The mounting portion 82 can be connected to a tubular member T or the like and is provided with a hole portion through which body fluid or polyps discharged from a patient flow.

[0370] The container 85 has a wall surface 86, a step portion 87, an opening portion 88, and a discharge portion 89. The wall surface 86 is configured to form the side wall and the bottom wall of the container 85. The step portion 87 is provided at an intermediate position of the inner side wall in the wall surface 86 so that the following partitioning portion 91 can be provided. The opening portion 88 is a portion blocked by the cover portion 81 and is provided at the upper portion of the container 85. The discharge portion 89 is provided at the lower portion of the container 85 and is configured to allow the body fluid flowing in from the opening portion 88 to flow downstream.

[0371] The partitioning portion 91 has a filter 92, a partition plate 93, and a support column 94. The filter 92 is provided with numerous hole portions to separate solid components such as polyps contained in the body fluid flowing in through the mounting portion 82 from the body fluid. The partition plates 93 are provided at a predetermined interval in the angular direction above the filter 92. The partition plates 93 are provided in a shape that divides the upper portion of the filter 92 in the circumferential direction in a plan view to provide a plurality of places for arranging the solid components separated from the body fluid on the filter 92. The partitioning portion 91 is configured to be relatively rotatable with respect to the container 85, and by rotating with respect to the mounting portion 82 to change the position of the partition plate 93, for example, the solid components can be intercepted and separated for each patient on the filter 92. The support columns 94 are provided integrally with the plurality of partition plates 93 at substantially the center of the partition plates 93. By being configured in this way, solid components such as polyps can be removed (separated) from the waste liquid to be processed relatively early.

[0372] The present invention includes the following forms and modes.

[0373] 1. A waste liquid treatment tool, comprising: a container provided with: an internal space capable of accommodating body fluid contained in or discharged from a human; and an opening portion capable of introducing the body fluid into the internal space by suction; a cover portion capable of being mounted on the container so as to block the opening portion of the container, and having an inflow portion through which the body fluid can flow into the internal space by the suction; A partitioning member, disposed in the interior space, divides the interior space into a first interior space on the proximal side of the opening portion and a second interior space on the distal side that is farther from the opening portion than the first interior space; and An excrement treatment agent, disposed in the second interior space of the container, forms the body fluid into a solid-like swelling substance by contacting the body fluid, The partitioning member allows the body fluid flowing into the interior space from the inflow portion to flow between the first interior space and the second interior space, and can cut off the flow of the swelling substance generated by contacting the body fluid flowing into the second interior space with the excrement treatment agent to the first interior space.

[0374] 2. The waste liquid treatment tool according to the above 1, wherein the partitioning member has: a first member that allows the body fluid to flow between the second interior space and the first interior space; and a second member having a higher rigidity than the first member.

[0375] 3. The waste liquid treatment tool according to the above 2, wherein the lid portion has an outflow portion that allows at least one of the gas discharged from the interior space and the body fluid to flow downstream through the suction. The second member has a first wall portion. In a state where the partitioning member is disposed in the interior space, the first wall portion is disposed in the first interior space and is disposed adjacent to the outflow portion between the inflow portion and the outflow portion.

[0376] 4. The waste liquid treatment tool according to the above 2 or 3, wherein the second member has: a covering portion that locally covers one side of the first member; and a second wall portion disposed at or near the outer peripheral edge portion of the covering portion. In a state where the partitioning member is disposed in the interior space, the second wall portion is disposed adjacent to the inflow portion in the first interior space.

[0377] 5. The waste liquid treatment tool according to any one of the above 1 to 4, wherein an intercepting portion can be installed at the inflow portion, and the intercepting portion includes a filter that can separate the solid components contained in the body fluid from the body fluid.

[0378] 6. The waste liquid treatment tool according to any one of the above 1 to 5, wherein a convex portion is provided on one of the lid portion and the partitioning member, and a concave portion that can engage with the convex portion is provided on the other, so that in a state where the lid portion is installed on the container, the partitioning member is positioned in the interior space.

[0379] 7. A downstream-side waste liquid treatment tool that can be connected to the waste liquid treatment tool according to any one of the above 1 to 6 via a tubular member, and has: A second container provided with the internal space and the opening; A second lid portion that can be attached to the second container so as to block the opening of the second container, having the inflow portion and a second outflow portion through which the gas discharged from the internal space can flow downstream by suction; The excrement treatment agent is disposed in the internal space of the second container and forms the swelling substance by contacting the body fluid; and A displacement member that cuts off the flow of the body fluid and the swelling substance downstream when the swelling substance generated by the contact between the excrement treatment agent and the body fluid reaches a predetermined height in the internal space.

[0380] 8. The downstream waste liquid treatment tool according to item 7 above, having a mounting member that can be mounted on the second lid portion, having a contact portion that holds the displacement member near the second outflow portion of the internal space when the displacement member does not cut off the flow of the body fluid and the swelling substance.

[0381] 9. The downstream waste liquid treatment tool according to item 8 above, wherein the displacement member has: a blocking portion that can at least partially block the flow path of the second outflow portion; and a fall prevention portion that can contact the contact portion of the mounting member and holds the displacement member in a position near the second outflow portion in the internal space by the contact.

[0382] 10. The downstream waste liquid treatment tool according to any one of items 7 to 9 above, wherein the displacement member has a floating portion provided at the lower end in the direction of gravity and can float the displacement member on the liquid surface in a state of contacting the liquid surface of the body fluid in the internal space.

[0383] 11. The downstream waste liquid treatment tool according to any one of items 7 to 10 above, wherein the displacement member has a circulation mechanism that allows suction of the gas while suppressing suction of the liquid during the suction.

[0384] The above is the description of the second invention.

[0385] This application is based on Japanese Patent Application No. 2022-173428 and Japanese Patent Application No. 2022-173431 filed on October 28, 2022, the disclosures of which are incorporated herein by reference in their entirety.

[0386] Description of reference numerals 10: Container, 10a: Container (second container), 11: Opening, 12: Inner space, 13: First inner space, 14: Second inner space, 20: Excrement treatment agent, 30: Cover part, 30a: Cover part (second cover part), 33: Connection part (inflow part), 34: Connection part (outflow part), 34a: Connection part (second outflow part), 35: Engagement recess, 40: Partition member, 41: First member, 42: Second member, 50: Connecting member, 60: Mounting member, 63: Contact part, 70: Displacement member, 71: Blocking part, 72: Anti-falling part, 75: Floating part, 80: Interception component (interception part), 92: Filter, 100: Waste liquid treatment tool, 100a: Downstream waste liquid treatment tool, h1: Insertion through-hole (flow mechanism), p1: Covering part, p3: Engagement protrusion, p4: First wall part, p5: Second wall part, T: Tubular member, w: Swelling substance.

Claims

1. A treating agent for treating waste liquid, characterized in that, Contains slaked lime and pepper.

2. The treating agent according to claim 1, characterized in that, The pepper is not in the form of a piperine extract.

3. The treatment agent according to claim 1, characterized in that, Contains a water-absorbing polymer.

4. The treating agent according to claim 1, characterized in that, The content ratio (mass%) of the slaked lime is 0.1 to 40 mass%, and the content ratio (mass%) of the pepper is 0.05 to 30 mass%.

5. The treatment agent according to claim 1, wherein Contains zinc oxide.

6. The treating agent according to claim 5, characterized in that, Contains at least one selected from the group consisting of lignin, bentonite, and zeolite.

7. The treatment agent according to claim 6, characterized in that, Also contains humic acid.

8. The treating agent according to claim 1, wherein The waste liquid includes excrement, blood, vomit, or body fluids discharged from humans or animals.

9. The treating agent according to claim 1, wherein The waste liquid contains at least one of indole and skatole as malodorous components.

10. The treatment agent according to claim 1, wherein For inhibiting or hindering the spore germination or proliferation of spore-forming bacteria.

11. The treating agent according to claim 10, characterized in that, The spore-forming bacterium is Clostridium difficile.

12. A method for inhibiting or impeding the germination or proliferation of spores of spore-forming bacteria, characterized in that, Has a step of bringing the waste liquid into contact with the treatment agent according to any one of claims 1 to 11.

13. A waste liquid treatment tool, characterized in that, Has: A container provided with: an internal space capable of accommodating body fluids contained in or discharged from a human; and an opening capable of introducing the body fluids into the internal space by suction. A lid portion capable of being mounted on the container so as to block the opening of the container, and having an inflow portion capable of allowing the body fluids to flow into the internal space by the suction. A partition member disposed in the internal space, dividing the internal space into a first internal space proximal to the opening and a second internal space distal to the opening and farther from the opening than the first internal space. And An excrement treatment agent disposed in the second internal space of the container, which forms the body fluids into a solid-like swelling substance by contacting the body fluids. The partition member can allow the body fluids flowing into the internal space from the inflow portion to flow between the first internal space and the second internal space, and can cut off the flow of the swelling substance generated by contacting the body fluids flowing into the second internal space with the excrement treatment agent to the first internal space.

14. The waste liquid treatment tool according to claim 13, wherein The partition member has: a first member capable of allowing the body fluids to flow between the second internal space and the first internal space. And a second member having a higher rigidity than the first member.

15. The waste liquid treatment tool according to claim 14, wherein The lid portion has an outflow portion capable of allowing at least one of the gas and the body fluids discharged from the internal space to flow downstream by the suction. The second member has a first wall portion, which is disposed in the first internal space in a state where the partition member is disposed in the internal space, and is disposed adjacent to the outflow portion between the inflow portion and the outflow portion.

16. The waste liquid treatment tool according to claim 14, characterized in that, The second member has: a covering portion that locally covers one side of the first member; and a second wall portion disposed at or near the outer peripheral edge of the covering portion, and disposed adjacent to the inflow portion in the first internal space in a state where the partition member is disposed in the internal space.

17. The waste liquid treatment tool according to claim 13, wherein An intercepting portion can be installed at the inflow portion, and the intercepting portion includes a filter capable of separating solid components contained in the body fluids from the body fluids.

18. The waste liquid treatment tool according to claim 13, wherein A convex portion is provided on one of the lid portion and the partition member, and a concave portion capable of engaging with the convex portion is provided on the other, so that the partition member is positioned in the internal space in a state where the lid portion is mounted on the container.

19. A downstream waste liquid treatment tool, characterized in that, It can be connected to the waste liquid treatment tool according to claim 13 via a tubular member, and has: A second container provided with the internal space and the opening; A second lid portion capable of being mounted on the second container so as to block the opening of the second container, having the inflow portion and a second outflow portion capable of allowing the gas discharged from the internal space to flow downstream through the suction; The excrement treatment agent is disposed in the internal space of the second container and forms the swelling substance by contacting the body fluid; And A displacement member that cuts off the flow of the body fluid and the swelling substance downstream when the swelling substance generated by the contact between the excrement treatment agent and the body fluid reaches a specified height in the internal space.

20. The downstream waste liquid treatment tool according to claim 19, characterized in that, It has a mounting member that can be mounted on the second lid portion and has an abutting portion that holds the displacement member near the second outflow portion of the internal space when the displacement member does not cut off the flow of the body fluid and the swelling substance.

21. The downstream waste liquid treatment tool according to claim 21, characterized in that, The displacement member has: a blocking portion capable of at least partially blocking the flow path of the second outflow portion; and a fall prevention portion capable of abutting against the abutting portion of the mounting member and holding the displacement member at a position near the second outflow portion in the internal space by the abutment.

22. The downstream waste liquid treatment tool according to claim 19, characterized in that, The displacement member has a floating portion provided at the lower end in the direction of gravity and capable of floating the displacement member on the liquid surface in a state of contacting the liquid surface of the body fluid in the internal space.

23. The downstream waste liquid treatment tool according to claim 19, wherein The displacement member has a circulation mechanism that allows the suction of gas while suppressing the suction of the liquid during the suction.

Images